{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:22:43Z","timestamp":1787696563088,"version":"build-2784847793"},"reference-count":361,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00985-1","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:00:40Z","timestamp":1787695240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From molecular pathogenesis to novel Therapeutic approaches - a review of recent advances in the treatment of peripheral T cell Lymphomas"],"prefix":"10.1186","volume":"14","author":[{"given":"Wee Lee","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"7","key":"985_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E, et al. The 5th edition of the world health organization classification of Haematolymphoid tumours: lymphoid neoplasms. Leukemia [Internet]. 2022;36(7):1720\u201348. Available from: https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"11","key":"985_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood [Internet]. 2022;140(11):1229\u201353. Available from: https:\/\/doi.org\/10.1182\/blood.2022015851.","journal-title":"Blood"},{"key":"985_CR3","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International T-Cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol [Internet]. 2008;26:4124\u201330. Available from: https:\/\/doi.org\/10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"issue":"12","key":"985_CR4","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.3324\/haematol.2023.282716","volume":"108","author":"B Bisig","year":"2023","unstructured":"Bisig B, Savage KJ, De Leval L. Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions. Haematologica [Internet]. 2023;108(12):3227\u201343. Available from: https:\/\/doi.org\/10.3324\/haematol.2023.282716.","journal-title":"Haematologica"},{"issue":"21","key":"985_CR5","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","volume":"131","author":"JS Van Arnam","year":"2018","unstructured":"Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood [Internet]. 2018;131(21):2320\u201330. Available from: https:\/\/doi.org\/10.1182\/blood-2017-11-764357.","journal-title":"Blood"},{"issue":"14","key":"985_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin\u2019s lymphoma. N Engl J Med [Internet]. 1993;328(14):1002\u201306. Available from: https:\/\/doi.org\/10.1056\/NEJM199304083281404.","journal-title":"N Engl J Med"},{"issue":"4","key":"985_CR7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","volume":"38","author":"EM McKelvey","year":"1976","unstructured":"McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer [Internet]. 1976;38(4):1484\u201393. Available from: https:\/\/doi.org\/10.1002\/1097-0142(197610)38:4%3C1484::AID-CNCR2820380407%3E3.0.CO;2-I.","journal-title":"Cancer [Internet]"},{"issue":"10","key":"985_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood [Internet]. 2014;124(10):1570\u201377. Available from: https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"key":"985_CR9","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.lanwpc.2021.100126","volume":"10","author":"SE Yoon","year":"2021","unstructured":"Yoon SE, Song Y, Kim SJ, Yoon DH, Chen T-Y, Koh Y, et al. Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Lancet Reg Health - West Pac [Internet]. 2021;10:100126. Available from: https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100126.","journal-title":"Lancet Reg Health - West Pac"},{"issue":"3","key":"985_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood.2020010387","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project. Blood [Internet]. 2021;138(3):213\u201320. Available from: https:\/\/doi.org\/10.1182\/blood.2020010387.","journal-title":"Blood"},{"issue":"3","key":"985_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","volume":"5","author":"A Shustov","year":"2021","unstructured":"Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the international T-Cell project. Blood Adv [Internet]. 2021;5(3):640\u201348. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2020001581.","journal-title":"Blood Adv"},{"issue":"7","key":"985_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cncr.30416","volume":"123","author":"KR Carson","year":"2017","unstructured":"Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer [Internet]. 2017;123(7):1174\u201383. Available from: https:\/\/doi.org\/10.1002\/cncr.30416.","journal-title":"Cancer"},{"issue":"16","key":"985_CR13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. JCO [Internet]. 2013;31(16):1970\u201376. Available from: https:\/\/doi.org\/10.1200\/JCO.2012.44.7524.","journal-title":"JCO"},{"key":"985_CR14","doi-asserted-by":"publisher","unstructured":"Bennani NN, Kim HJ, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, et al. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer [Internet]. 2022;10(6):e004984. Available from: https:\/\/doi.org\/10.1136\/jitc-2022-004984.","DOI":"10.1136\/jitc-2022-004984"},{"issue":"14","key":"985_CR15","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1182\/bloodadvances.2023012531","volume":"8","author":"M Brink","year":"2024","unstructured":"Brink M, Huisman F, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, et al. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands cancer registry. Blood Adv [Internet]. 2024;8(14):3619\u201328. Available from: 10.1182\/bloodadvances.2023012531.","journal-title":"Blood Adv"},{"issue":"25","key":"985_CR16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med [Internet]. 2002;346(25):1937\u201347. Available from: https:\/\/doi.org\/10.1056\/NEJMoa012914.","journal-title":"N Engl J Med"},{"issue":"5","key":"985_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. The Lancet Oncol [Internet]. 2006;7(5):379\u201391. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7.","journal-title":"The Lancet Oncol"},{"issue":"Supplement 1","key":"985_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood-2024-197938","volume":"144","author":"G Salles","year":"2024","unstructured":"Salles G, Morschhauser F, Sehn LH, Herrera AF, Friedberg JW, Trn\u011bn\u00fd M, et al. Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. Blood [Internet]. 2024;144(Supplement 1):469\u2013469. Available from: https:\/\/doi.org\/10.1182\/blood-2024-197938.","journal-title":"Blood"},{"issue":"1","key":"985_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. The Lancet Oncol [Internet]. 2019;20(1):31\u201342. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.","journal-title":"The Lancet Oncol"},{"issue":"10","key":"985_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncol [Internet]. 2021;22(10):1403\u201315. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2.","journal-title":"The Lancet Oncol"},{"issue":"10254","key":"985_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet [Internet]. 2020;396(10254):839\u201352. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"24","key":"985_CR22","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med [Internet]. 2022;387(24):2220\u201331. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"issue":"12","key":"985_CR23","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell\u2013engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol [Internet]. 2023;41(12):2238\u201347. Available from: https:\/\/doi.org\/10.1200\/JCO.22.01725.","journal-title":"J Clin Oncol"},{"issue":"7","key":"985_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood [Internet]. 2024, Available from: 2025;145(7):708\u201319. https:\/\/doi.org\/10.1182\/blood.2024025454.","journal-title":"Blood"},{"key":"985_CR25","doi-asserted-by":"publisher","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica [Internet]. 2019;104(5):e211\u20134. Available from: https:\/\/doi.org\/10.3324\/haematol.2018.205229. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6518912\/.","DOI":"10.3324\/haematol.2018.205229"},{"issue":"12","key":"985_CR26","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","volume":"5","author":"CS Tam","year":"2021","unstructured":"Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv [Internet]. 2021;5(12):2577\u201385. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2020004074.","journal-title":"Blood Adv"},{"issue":"10121","key":"985_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet [Internet]. 2018;391(10121):659\u201367. Available from: https:\/\/doi.org\/10.1016\/s0140-6736(17)33108-2.","journal-title":"Lancet"},{"key":"985_CR28","doi-asserted-by":"publisher","first-page":"101779","DOI":"10.1016\/j.eclinm.2022.101779","volume":"56","author":"R Ramchandren","year":"2023","unstructured":"Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, et al. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed\/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine [Internet]. 2023;56:101779. Available from: https:\/\/doi.org\/10.1016\/j.eclinm.2022.101779.","journal-title":"EClinicalMedicine"},{"issue":"10168","key":"985_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet [Internet]. 2019;393(10168):229\u201340. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"issue":"9","key":"985_CR30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol [Internet]. 2011;29(9):1182\u201389. Available from: https:\/\/doi.org\/10.1200\/JCO.2010.29.9024.","journal-title":"J Clin Oncol"},{"issue":"23","key":"985_CR31","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol [Internet]. 2015;33(23):2492\u201399. Available from: https:\/\/doi.org\/10.1200\/JCO.2014.59.2782.","journal-title":"J Clin Oncol"},{"issue":"1","key":"985_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol [Internet]. 2014;7(1):11. Available from: https:\/\/doi.org\/10.1186\/1756-8722-7-11.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"985_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2020-134440","volume":"136","author":"E Bachy","year":"2020","unstructured":"Bachy E, Camus V, Thieblemont C, Casasnovas R-O, Ysebaert L, Damaj GL, et al. Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood [Internet]. 2020;136(Supplement 1):32\u201333. Available from: https:\/\/doi.org\/10.1182\/blood-2020-134440.","journal-title":"Blood"},{"issue":"10","key":"985_CR34","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1182\/bloodadvances.2025018455","volume":"10","author":"J Ruan","year":"2026","unstructured":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen P, Mou E, et al. Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study. Blood Adv [Internet]. 2026;10(10):3480\u201393. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2025018455.","journal-title":"Blood Adv"},{"issue":"18","key":"985_CR35","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood.2023021788","volume":"144","author":"E Marchi","year":"2024","unstructured":"Marchi E, Craig JW, Kalac M. Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL). Blood [Internet]. 2024;144(18):1898\u2013909. Available from: https:\/\/doi.org\/10.1182\/blood.2023021788.","journal-title":"Blood"},{"issue":"9","key":"985_CR36","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","volume":"129","author":"T Lamy","year":"2017","unstructured":"Lamy T, Moignet A, Loughran TP Jr. LGL leukemia: from pathogenesis to treatment. Blood [Internet]. 2017;129(9):1082\u201394. Available from: https:\/\/doi.org\/10.1182\/blood-2016-08-692590.","journal-title":"Blood"},{"issue":"14","key":"985_CR37","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2019000402","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood [Internet]. 2019;134(14):1132\u201343. Available from: https:\/\/doi.org\/10.1182\/blood.2019000402. https:\/\/ashpublications.org\/blood\/article\/134\/14\/1132\/374897\/Consensus-criteria-for-diagnosis-staging-and.","journal-title":"Blood"},{"issue":"4","key":"985_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cas.12617","volume":"106","author":"A Utsunomiya","year":"2015","unstructured":"Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci [Internet]. 2015;106(4):344\u201351. Available from: https:\/\/doi.org\/10.1111\/cas.12617.","journal-title":"Cancer Sci"},{"issue":"1","key":"985_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26760","volume":"98","author":"AC Hristov","year":"2023","unstructured":"Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol [Internet]. 2023;98(1):193\u2013209. Available from: https:\/\/doi.org\/10.1002\/ajh.26760.","journal-title":"Am J Hematol"},{"issue":"18","key":"985_CR40","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2023021786","volume":"144","author":"L de Leval","year":"2024","unstructured":"de Leval L, Gaulard P, Dogan A. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas. Blood [Internet]. 2024;144(18):1855\u201372. Available from: https:\/\/doi.org\/10.1182\/blood.2023021786.","journal-title":"Blood"},{"issue":"20","key":"985_CR41","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood [Internet]. 2016;127(20):2375\u201390. Available from: https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"7","key":"985_CR42","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3324\/haematol.2009.008250","volume":"94","author":"B Falini","year":"2009","unstructured":"Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica [Internet]. 2009;94(7):897\u2013900. Available from: https:\/\/doi.org\/10.3324\/haematol.2009.008250.","journal-title":"Haematologica"},{"issue":"7","key":"985_CR43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","volume":"129","author":"MT Werner","year":"2017","unstructured":"Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood [Internet]. 2017;129(7):823\u201331. Available from: https:\/\/doi.org\/10.1182\/blood-2016-05-717793.","journal-title":"Blood"},{"issue":"9","key":"985_CR44","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2008.20.9759","volume":"28","author":"R Piva","year":"2010","unstructured":"Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol [Internet]. 2010;28(9):1583\u201390. Available from: https:\/\/doi.org\/10.1200\/JCO.2008.20.9759.","journal-title":"J Clin Oncol"},{"issue":"19","key":"985_CR45","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood [Internet]. 2014;123(19):2915\u201323. Available from: https:\/\/doi.org\/10.1182\/blood-2013-11-536359.","journal-title":"Blood"},{"issue":"1","key":"985_CR46","doi-asserted-by":"publisher","first-page":"10087","DOI":"10.1038\/ncomms10087","volume":"7","author":"TIM Malcolm","year":"2016","unstructured":"Malcolm TIM, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun [Internet]. 2016;7(1):10087. Available from: https:\/\/doi.org\/10.1038\/ncomms10087.","journal-title":"Nat Commun"},{"issue":"6","key":"985_CR47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3324\/haematol.2019.238766","volume":"106","author":"H Larose","year":"2021","unstructured":"Larose H, Prokoph N, Matthews JD, Schlederer M, H\u00f6gler S, Alsulami AF, et al. Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to notch both as a key pathway and a potential therapeutic target. Haematologica [Internet]. 2021;106(6):1693\u2013704. Available from: https:\/\/doi.org\/10.3324\/haematol.2019.238766.","journal-title":"Haematologica"},{"issue":"9","key":"985_CR48","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood [Internet]. 2014;124(9):1473\u201380. Available from: https:\/\/doi.org\/10.1182\/blood-2014-04-571091.","journal-title":"Blood"},{"issue":"3","key":"985_CR49","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","volume":"117","author":"AL Feldman","year":"2011","unstructured":"Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood [Internet]. 2011;117(3):915\u201319. Available from: https:\/\/doi.org\/10.1182\/blood-2010-08-303305.","journal-title":"Blood"},{"issue":"4","key":"985_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","volume":"130","author":"MB Pedersen","year":"2017","unstructured":"Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood [Internet]. 2017;130(4):554\u201357. Available from: https:\/\/doi.org\/10.1182\/blood-2016-12-755496.","journal-title":"Blood"},{"issue":"13","key":"985_CR51","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","volume":"132","author":"RA Luchtel","year":"2018","unstructured":"Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, et al. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood [Internet]. 2018;132(13):1386\u201398. Available from: https:\/\/doi.org\/10.1182\/blood-2018-03-838524.","journal-title":"Blood"},{"issue":"11","key":"985_CR52","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","volume":"120","author":"G Vasmatzis","year":"2012","unstructured":"Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood [Internet]. 2012;120(11):2280\u201389. Available from: https:\/\/doi.org\/10.1182\/blood-2012-03-419937.","journal-title":"Blood"},{"issue":"4","key":"985_CR53","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell [Internet]. 2015;27(4):516\u201332. Available from: https:\/\/doi.org\/10.1016\/j.ccell.2015.03.006.","journal-title":"Cancer Cell"},{"issue":"25","key":"985_CR54","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2014-07-588434","volume":"124","author":"T Velusamy","year":"2014","unstructured":"Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood [Internet]. 2014;124(25):3768\u201371. Available from: https:\/\/doi.org\/10.1182\/blood-2014-07-588434.","journal-title":"Blood"},{"issue":"2","key":"985_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/annonc\/mdv575","volume":"27","author":"C Laurent","year":"2016","unstructured":"Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol [Internet]. 2016;27(2):306\u201314. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdv575.","journal-title":"Ann Oncol"},{"issue":"3","key":"985_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/PAS.0000000000000985","volume":"42","author":"MC Ferrufino-Schmidt","year":"2018","unstructured":"Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol [Internet]. 2018;42(3):293\u2013305. Available from: https:\/\/doi.org\/10.1097\/PAS.0000000000000985.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"985_CR57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41379-018-0130-7","volume":"32","author":"A Di Napoli","year":"2019","unstructured":"Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C, et al. Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. Mod Pathol [Internet]. 2019;32(2):216\u201330. Available from: https:\/\/doi.org\/10.1038\/s41379-018-0130-7.","journal-title":"Mod Pathol"},{"issue":"6","key":"985_CR58","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3324\/haematol.2019.245860","volume":"106","author":"N Oishi","year":"2021","unstructured":"Oishi N, Hundal T, Phillips JL, Dasari S, Hu G, Viswanatha DS, et al. Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica [Internet]. 2021;106(6):1714\u201324. Available from: https:\/\/doi.org\/10.3324\/haematol.2019.245860.","journal-title":"Haematologica"},{"issue":"10","key":"985_CR59","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.19.02778","volume":"38","author":"ES Jaffe","year":"2020","unstructured":"Jaffe ES, Ashar BS, Clemens MW, Feldman AL, Gaulard P, Miranda RN, et al. Best practices guideline for the pathologic diagnosis of breast implant\u2013associated anaplastic large-cell lymphoma. J Clin Oncol [Internet]. 2020;38(10):1102\u201311. Available from: https:\/\/doi.org\/10.1200\/JCO.19.02778.","journal-title":"J Clin Oncol"},{"issue":"5","key":"985_CR60","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","volume":"132","author":"N Oishi","year":"2018","unstructured":"Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, et al. Genetic subtyping of breast implant\u2013associated anaplastic large cell lymphoma. Blood [Internet]. 2018;132(5):544\u201347. Available from: https:\/\/doi.org\/10.1182\/blood-2017-12-821868.","journal-title":"Blood"},{"key":"985_CR61","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood.2019001904","volume":"135","author":"C Laurent","year":"2020","unstructured":"Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. Blood [Internet]. 2020;135:360\u201370. Available from: https:\/\/doi.org\/10.1182\/blood.2019001904.","journal-title":"Blood"},{"issue":"11","key":"985_CR62","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, Reynies AD, Huang Y-L, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood [Internet]. 2007;109(11):4952\u201363. Available from: https:\/\/doi.org\/10.1182\/blood-2006-10-055145.","journal-title":"Blood"},{"issue":"11","key":"985_CR63","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell\u2013derived lymphomas. Blood [Internet]. 2016;128(11):1490\u2013502. Available from: https:\/\/doi.org\/10.1182\/blood-2016-02-698977.","journal-title":"Blood"},{"key":"985_CR64","doi-asserted-by":"publisher","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais J-P, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica [Internet]. 2017;102(4):e148\u201351. Available from: https:\/\/doi.org\/10.3324\/haematol.2016.158428.","DOI":"10.3324\/haematol.2016.158428"},{"issue":"5","key":"985_CR65","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","volume":"148","author":"L de Leval","year":"2010","unstructured":"de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol [Internet]. 2010;148(5):673\u201389. Available from: https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08003.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"985_CR66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/PAS.0000000000000555","volume":"40","author":"SL Ondrejka","year":"2016","unstructured":"Ondrejka SL, Grzywacz B, Bodo J, Makishima H, Polprasert C, Said JW, et al. Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features. Am J Surg Pathol [Internet]. 2016;40(3):335\u201341. Available from: https:\/\/doi.org\/10.1097\/PAS.0000000000000555.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"985_CR67","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/path.5376","volume":"250","author":"W-Q Yao","year":"2020","unstructured":"Yao W-Q, Wu F, Zhang W, Chuang S-S, Thompson JS, Chen Z, et al. Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. The J Pathol [Internet]. 2020;250(3):346\u201357. Available from: https:\/\/doi.org\/10.1002\/path.5376.","journal-title":"The J Pathol"},{"issue":"21","key":"985_CR68","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood [Internet]. 2018;132(21):2305\u201309. Available from: https:\/\/doi.org\/10.1182\/blood-2018-04-840538.","journal-title":"Blood"},{"issue":"5","key":"985_CR69","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","volume":"33","author":"Y Huang","year":"2009","unstructured":"Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol [Internet]. 2009;33(5):682\u201390. Available from: https:\/\/doi.org\/10.1097\/PAS.0b013e3181971591.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"985_CR70","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2019002401","volume":"135","author":"K Debackere","year":"2020","unstructured":"Debackere K, van der Krogt J-A, Tousseyn T, Ferreiro JAF, Van Roosbroeck K, Marcelis L, et al. FER and FES tyrosine kinase fusions in follicular T-cell lymphoma. Blood [Internet]. 2020;135(8):584\u201388. Available from: https:\/\/doi.org\/10.1182\/blood.2019002401.","journal-title":"Blood"},{"issue":"2","key":"985_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.leu.2404045","volume":"20","author":"B Streubel","year":"2006","unstructured":"Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia [Internet]. 2006;20(2):313\u201318. Available from: https:\/\/doi.org\/10.1038\/sj.leu.2404045.","journal-title":"Leukemia"},{"issue":"6","key":"985_CR72","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/PAS.0000000000000188","volume":"38","author":"ED Hsi","year":"2014","unstructured":"Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T\/NK-cell lymphomas. A North American PTCL study group project: a north American PTCL study group project. Am J Surg Pathol [Internet]. 2014;38(6):768\u201375. Available from: https:\/\/doi.org\/10.1097\/PAS.0000000000000188.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"985_CR73","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00428-004-1077-2","volume":"445","author":"E Geissinger","year":"2004","unstructured":"Geissinger E, Odenwald T, Lee S-S, Bonzheim I, Roth S, Reimer P, et al. Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert?s) variant are often derived from CD8+ cytotoxic T-cells. Virchows Arch [Internet]. 2004;445(4):334\u201343. Available from: https:\/\/doi.org\/10.1007\/s00428-004-1077-2.","journal-title":"Virchows Arch"},{"issue":"10","key":"985_CR74","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1182\/blood-2004-03-1037","volume":"104","author":"I Bonzheim","year":"2004","unstructured":"Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, Rosenwald A, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood [Internet]. 2004;104(10):3358\u201360. Available from: https:\/\/doi.org\/10.1182\/blood-2004-03-1037.","journal-title":"Blood"},{"key":"985_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-99716-2_2","volume":"176","author":"J Iqbal","year":"2019","unstructured":"Iqbal J, Amador C, McKeithan TW, Chan WC. Molecular and genomic landscape of peripheral T-cell lymphoma. Cancer Treat Res [Internet]. 2019;176:31\u201368. Available from: https:\/\/doi.org\/10.1007\/978-3-319-99716-2_2.","journal-title":"Cancer Treat Res"},{"issue":"15","key":"985_CR76","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood [Internet]. 2019;133(15):1664\u201376. Available from: https:\/\/doi.org\/10.1182\/blood-2018-09-872549.","journal-title":"Blood"},{"issue":"24","key":"985_CR77","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood.2019000779","volume":"134","author":"C Amador","year":"2019","unstructured":"Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma\u2013NOS by immunohistochemistry. Blood [Internet]. 2019;134(24):2159\u201370. Available from: https:\/\/doi.org\/10.1182\/blood.2019000779.","journal-title":"Blood"},{"issue":"12","key":"985_CR78","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia [Internet]. 2019;33(12):2867\u201383. Available from: https:\/\/doi.org\/10.1038\/s41375-019-0473-1.","journal-title":"Leukemia"},{"issue":"5","key":"985_CR79","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2015.357","volume":"30","author":"J Rohr","year":"2016","unstructured":"Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia [Internet]. 2016;30(5):1062\u201370. Available from: https:\/\/doi.org\/10.1038\/leu.2015.357.","journal-title":"Leukemia"},{"issue":"7","key":"985_CR80","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/PAS.0000000000001708","volume":"45","author":"MJ Fitzpatrick","year":"2021","unstructured":"Fitzpatrick MJ, Massoth LR, Marcus C, Vergilio J-A, Severson E, Duncan D, et al. JAK2 rearrangements are a recurrent alteration in CD30+ systemic T-cell lymphomas with anaplastic morphology. Am J Surg Pathol [Internet]. 2021;45(7):895\u2013904. Available from: https:\/\/doi.org\/10.1097\/PAS.0000000000001708.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"985_CR81","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.xcrm.2024.101416","volume":"5","author":"Y-H Huang","year":"2024","unstructured":"Huang Y-H, Qiu Y-R, Zhang Q-L, Cai M-C, Yu H, Zhang J-M, et al. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell Rep Med [Internet]. 2024;5(2):101416. Available from: https:\/\/doi.org\/10.1016\/j.xcrm.2024.101416.","journal-title":"Cell Rep Med"},{"key":"985_CR82","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3324\/haematol.2023.284448","volume":"110","author":"P Stephan","year":"2025","unstructured":"Stephan P, Perrot J, Voisin A, Barbery M, Andrieu T, Grimont M, et al. Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets. Haematologica [Internet]. 2025;110:129\u201341. Available from: https:\/\/doi.org\/10.3324\/haematol.2023.284448.","journal-title":"Haematologica"},{"issue":"1","key":"985_CR83","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1756-8722-4-50","volume":"4","author":"J Wang","year":"2011","unstructured":"Wang J, Ke X-Y. The four types of tregs in malignant lymphomas. J Hematol Oncol [Internet]. 2011;4(1):50. Available from: https:\/\/doi.org\/10.1186\/1756-8722-4-50.","journal-title":"J Hematol Oncol"},{"issue":"44","key":"985_CR84","doi-asserted-by":"publisher","first-page":"76231","DOI":"10.18632\/oncotarget.19301","volume":"8","author":"JS Ham","year":"2017","unstructured":"Ham JS, Park HY, Ryu KJ, Ko YH, Kim WS, Kim SJ. Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. Oncotarget [Internet]. 2017;8(44):76231\u201340. Available from: https:\/\/doi.org\/10.18632\/oncotarget.19301.","journal-title":"Oncotarget"},{"issue":"17","key":"985_CR85","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/bloodadvances.2018018754","volume":"2","author":"T Sugio","year":"2018","unstructured":"Sugio T, Miyawaki K, Kato K, Sasaki K, Yamada K, Iqbal J, et al. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv [Internet]. 2018;2(17):2242\u201352. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2018018754.","journal-title":"Blood Adv"},{"issue":"3","key":"985_CR86","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00277-020-04389-5","volume":"100","author":"Q Zhu","year":"2021","unstructured":"Zhu Q, Deng X, Yao W, Chen Z, Ye Y, Gao L, et al. Novel tumour\u2013infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma. Ann Hematol [Internet]. 2021;100(3):715\u201323. Available from: https:\/\/doi.org\/10.1007\/s00277-020-04389-5.","journal-title":"Ann Hematol"},{"issue":"1","key":"985_CR87","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41375-021-01321-2","volume":"36","author":"JC Pritchett","year":"2022","unstructured":"Pritchett JC, Yang Z-Z, Kim HJ, Villasboas JC, Tang X, Jalali S, et al. High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia [Internet]. 2022;36(1):165\u201376. Available from: https:\/\/doi.org\/10.1038\/s41375-021-01321-2.","journal-title":"Leukemia"},{"key":"985_CR88","doi-asserted-by":"publisher","unstructured":"Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A [Internet]. 2017;114(36):E7554\u201363. Available from: https:\/\/doi.org\/10.1073\/pnas.1703094114.","DOI":"10.1073\/pnas.1703094114"},{"issue":"2","key":"985_CR89","doi-asserted-by":"publisher","first-page":"227","DOI":"10.7326\/0003-4819-76-2-227","volume":"76","author":"CM Bagley Jr","year":"1972","unstructured":"Bagley CM Jr, Devita VT Jr, Berard CW, Canellos GP. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med [Internet]. 1972;76(2):227\u201334. Available from: https:\/\/doi.org\/10.7326\/0003-4819-76-2-227.","journal-title":"Ann Intern Med"},{"issue":"10","key":"985_CR90","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol [Internet]. 2004;15(10):1467\u201375. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdh392.","journal-title":"Ann Oncol"},{"issue":"21","key":"985_CR91","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood.v124.21.4434.4434","volume":"124","author":"L Pinter-Brown","year":"2014","unstructured":"Pinter-Brown L, Foss FM, Carson KR, Horwitz SM, Rosen ST, Pro B, et al. Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T-cell lymphoma (PTCL). Blood [Internet]. 2014;124(21):4434\u20134434. Available from: https:\/\/doi.org\/10.1182\/blood.v124.21.4434.4434.","journal-title":"Blood"},{"issue":"12","key":"985_CR92","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood [Internet]. 2011;117(12):3402\u201308. Available from: https:\/\/doi.org\/10.1182\/blood-2010-09-310342.","journal-title":"Blood"},{"key":"985_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol [Internet]. 2011, 2011: 2011:1\u201314. Available from: https:\/\/doi.org\/10.5402\/2011\/623924.","journal-title":"ISRN Hematol"},{"issue":"18","key":"985_CR94","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood [Internet]. 2010;116(18):3418\u201325. Available from: https:\/\/doi.org\/10.1182\/blood-2010-02-270785.","journal-title":"Blood"},{"key":"985_CR95","doi-asserted-by":"publisher","unstructured":"Brink M, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood [Internet]. 2022;140(9):1009\u201319. Available from: https:\/\/doi.org\/10.1182\/blood.2021015114.","DOI":"10.1182\/blood.2021015114"},{"issue":"4","key":"985_CR96","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood [Internet]. 2003;102(4):1458\u201365. Available from: https:\/\/doi.org\/10.1182\/blood-2003-01-0039.","journal-title":"Blood"},{"issue":"11","key":"985_CR97","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/blood.V106.11.610.610","volume":"106","author":"KJ Hamblett","year":"2005","unstructured":"Hamblett KJ, Barton J, Cerveny CG, Andreyka JB, Kissler KM, Okeley NM, et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies. Blood [Internet]. 2005;106(11):610\u2013610. Available from: https:\/\/doi.org\/10.1182\/blood.V106.11.610.610.","journal-title":"Blood"},{"issue":"11","key":"985_CR98","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/blood.V108.11.231.231","volume":"108","author":"NM Okeley","year":"2006","unstructured":"Okeley NM, Alley SC, Cerveny CG, Andreyka J, Sanderson RJ, Anderson M, et al. Specific tumor targeting and potent bystander killing with SGN-35, an anti-CD30 antibody drug conjugate. Blood [Internet]. 2006;108(11):231\u2013231. Available from: https:\/\/doi.org\/10.1182\/blood.V108.11.231.231.","journal-title":"Blood"},{"issue":"3","key":"985_CR99","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol [Internet]. 2022;33(3):288\u201398. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002.","journal-title":"Ann Oncol"},{"key":"985_CR100","doi-asserted-by":"publisher","unstructured":"Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol [Internet]. 2003;14(1):i5\u201310. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdg702.","DOI":"10.1093\/annonc\/mdg702"},{"key":"985_CR101","doi-asserted-by":"publisher","unstructured":"Tay T, Somasundaram N, Lim C, Khoo LP, Goh AZK, Lee YS, et al. Treatment outcomes of T and natural-killer\/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. Cancer Rep [Internet]. 2022;5(9):e1552. Available from: https:\/\/doi.org\/10.1002\/cnr2.1552.","DOI":"10.1002\/cnr2.1552"},{"issue":"7","key":"985_CR102","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","volume":"77","author":"T Philip","year":"1991","unstructured":"Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood [Internet]. 1991;77(7):1587\u201392. Available from: https:\/\/doi.org\/10.1182\/blood.V77.7.1587.1587.","journal-title":"Blood"},{"issue":"6","key":"985_CR103","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"WS Velasquez","year":"1994","unstructured":"Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol [Internet]. 1994;12(6):1169\u201376. Available from: https:\/\/doi.org\/10.1200\/JCO.1994.12.6.1169.","journal-title":"J Clin Oncol"},{"issue":"1","key":"985_CR104","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3816\/clm.2005.n.030","volume":"6","author":"M Crump","year":"2005","unstructured":"Crump M, Shepherd L, Lin B. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin\u2019s lymphoma. Clin Lymphoma [Internet]. 2005;6(1):56\u201360. Available from: https:\/\/doi.org\/10.3816\/clm.2005.n.030.","journal-title":"Clin Lymphoma"},{"issue":"25","key":"985_CR105","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol [Internet]. 2012;30(25):3093\u201399. Available from: https:\/\/doi.org\/10.1200\/JCO.2011.40.2719.","journal-title":"J Clin Oncol"},{"issue":"9","key":"985_CR106","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study: upfront transplant in PTCL remission. Cancer [Internet]. 2019;125(9):1507\u201317. Available from: https:\/\/doi.org\/10.1002\/cncr.31861.","journal-title":"Cancer"},{"issue":"6","key":"985_CR107","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41409-024-02254-x","volume":"59","author":"L Girard","year":"2024","unstructured":"Girard L, Koh YJ, Koh LP, Chee YL, Chan HL, Lee J, et al. Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis. Bone Marrow Transpl [Internet]. 2024;59(6):838\u201348. Available from: https:\/\/doi.org\/10.1038\/s41409-024-02254-x.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"985_CR108","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/bjh.19317","volume":"204","author":"P Yang","year":"2024","unstructured":"Yang P, Cai M, Cao Y, Fan S, Tang W, Ji M, et al. Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: a multicentre real-world analysis. Br J Haematol [Internet]. 2024;204(4):1414\u201321. Available from: https:\/\/doi.org\/10.1111\/bjh.19317.","journal-title":"Br J Haematol"},{"issue":"1","key":"985_CR109","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol [Internet]. 2009;27(1):106\u201313. Available from: https:\/\/doi.org\/10.1200\/JCO.2008.17.4870.","journal-title":"J Clin Oncol"},{"issue":"6","key":"985_CR110","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.annonc.2025.01.023","volume":"36","author":"F d\u2019Amore","year":"2025","unstructured":"d\u2019Amore F, Federico M, de Leval L, Ellin F, Hermine O, Kim WS, et al. Peripheral T- and natural killer-cell lymphomas: ESMO\u2013EHA clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2025;36(6):626\u201344. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2025.01.023.","journal-title":"Ann Oncol"},{"issue":"11","key":"985_CR111","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American society for Blood and marrow transplantation. Biol Blood Marrow Transpl [Internet]. 2017;23(11):1826\u201338. Available from: https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.027.","journal-title":"Biol Blood Marrow Transpl"},{"key":"985_CR112","unstructured":"National Comprehensive Cancer Network. B cell lymphomas (version 2. 2026). Accessed 3rd March 2026 [Internet]. [https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. 2026 Mar 3]."},{"issue":"19","key":"985_CR113","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","volume":"6","author":"KJ Savage","year":"2022","unstructured":"Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv [Internet]. 2022;6(19):5550\u201355. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2020003971.","journal-title":"Blood Adv"},{"issue":"5","key":"985_CR114","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol [Internet]. 2017;176(5):750\u201358. Available from: https:\/\/doi.org\/10.1111\/bjh.14477.","journal-title":"Br J Haematol"},{"issue":"11","key":"985_CR115","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transpl [Internet]. 2025;60(11):1499\u2013525. Available from: https:\/\/doi.org\/10.1038\/s41409-025-02701-3.","journal-title":"Bone Marrow Transpl"},{"key":"985_CR116","doi-asserted-by":"publisher","unstructured":"Shumilov E, Ngoya M, Berning P, Devillier R, Forcade E, Schroeder T, et al. Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party. J Hematol Oncol [Internet]. 2026;19. Available from: 1). https:\/\/doi.org\/10.1186\/s13045-026-01783-w.","DOI":"10.1186\/s13045-026-01783-w"},{"issue":"Supplement 1","key":"985_CR117","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-138542","volume":"136","author":"N Mehta-Shah","year":"2020","unstructured":"Mehta-Shah N, Kommalapati A, Teja S, Cashen AF, Dahi PB, Sauter CS, et al. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. Blood [Internet]. 2020;136(Supplement 1):35\u201336. Available from: https:\/\/doi.org\/10.1182\/blood-2020-138542.","journal-title":"Blood"},{"issue":"14","key":"985_CR118","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant J-P, Mohty M, et al. Graft-versus-lymphoma effect for Aggressive T-cell lymphomas in adults: A study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire. J Clin Oncol [Internet]. 2008;26(14):2264\u201371. Available from: https:\/\/doi.org\/10.1200\/JCO.2007.14.1366.","journal-title":"J Clin Oncol"},{"issue":"1","key":"985_CR119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","volume":"12","author":"N Epperla","year":"2019","unstructured":"Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, et al. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol [Internet]. 2019;12(1):6. Available from: https:\/\/doi.org\/10.1186\/s13045-018-0696-z.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"985_CR120","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41375-022-01545-w","volume":"36","author":"K Kameda","year":"2022","unstructured":"Kameda K, Kako S, Kim S-W, Usui Y, Kato K, Fukuda T, et al. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia [Internet]. 2022;36(5):1361\u201370. Available from: https:\/\/doi.org\/10.1038\/s41375-022-01545-w.","journal-title":"Leukemia"},{"issue":"36","key":"985_CR121","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","volume":"35","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol [Internet]. 2017;35(36):4019\u201326. Available from: https:\/\/doi.org\/10.1200\/JCO.2017.73.8195.","journal-title":"J Clin Oncol"},{"issue":"25","key":"985_CR122","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood [Internet]. 2017;130(25):2709\u201317. Available from: https:\/\/doi.org\/10.1182\/blood-2017-05-780049.","journal-title":"Blood"},{"issue":"12","key":"985_CR123","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","volume":"21","author":"H-Z Lee","year":"2015","unstructured":"Lee H-Z, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, Habtemariam BA, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res [Internet]. 2015;21(12):2666\u201370. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3119.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"985_CR124","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol [Internet]. 2014;32(11):1157\u201363. Available from: https:\/\/doi.org\/10.1200\/JCO.2013.52.0924.","journal-title":"J Clin Oncol"},{"issue":"8","key":"985_CR125","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol [Internet]. 2015;26(8):1766\u201371. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdv237.","journal-title":"Ann Oncol"},{"key":"985_CR126","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/01.hs9.0000843764.15785.8c","volume":"6","author":"W-S Kim","year":"2022","unstructured":"Kim W-S, Yoon D-H, Song Y, Yang H, Cao J, Ji D, et al. S218: a phase i\/ii study of golidocitinib, a selective jak1 inhibitor, in refractory or relapsed peripheral t cell lymphoma. HemaSphere [Internet]. 2022;6:119\u201320. Available from: https:\/\/doi.org\/10.1097\/01.hs9.0000843764.15785.8c.","journal-title":"HemaSphere"},{"issue":"1","key":"985_CR127","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","volume":"25","author":"Y Song","year":"2024","unstructured":"Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 part B): a single-arm, multinational, phase 2 study. The Lancet Oncol [Internet]. 2024;25(1):117\u201325. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(23)00589-2.","journal-title":"The Lancet Oncol"},{"issue":"12","key":"985_CR128","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","volume":"25","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, C\u00f3rdoba R, et al. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncol [Internet]. 2024;25(12):1602\u201313. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(24)00503-5.","journal-title":"The Lancet Oncol"},{"key":"985_CR129","unstructured":"EZHARMIA\u00ae. Approved in Japan as first dual EZH1 and EZH2 inhibitor therapy for patients with peripheral T-Cell lymphoma [Internet]. [https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202209\/20220926_E.pdf. 2026 Mar 10]"},{"key":"985_CR130","doi-asserted-by":"publisher","unstructured":"Tiger YK, Atmuri U, Iyer SP. Trial in progress: a phase 3, randomized, open-label study comparing the efficacy and safety of the combination of beleodaq-CHOP or folotyn-cop to the CHOP regimen alone in newly diagnosed patients with peripheral T- Cell lymphoma - crescendo. Blood [Internet]. 2024;144(Supplement 1):.3123.1\u20133123.1. Available from: https:\/\/doi.org\/10.1182\/blood-2024-197991.","DOI":"10.1182\/blood-2024-197991"},{"issue":"26","key":"985_CR131","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood [Internet]. 2021;138(26):2828\u201337. Available from: https:\/\/doi.org\/10.1182\/blood.2021013379.","journal-title":"Blood"},{"key":"985_CR132","doi-asserted-by":"publisher","unstructured":"Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, et al. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol [Internet]. 2024;11(6):e406\u201314. Available from: https:\/\/doi.org\/10.1016\/S2352-3026(24)00102-9.","DOI":"10.1016\/S2352-3026(24)00102-9"},{"issue":"6","key":"985_CR133","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol [Internet]. 2012;30(6):631\u201336. Available from: https:\/\/doi.org\/10.1200\/JCO.2011.37.4223.","journal-title":"J Clin Oncol"},{"issue":"S3","key":"985_CR134","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hon.70096_855","volume":"43","author":"K Cwynarski","year":"2025","unstructured":"Cwynarski K, Domingo-Domenech E, Sidransky D, Bentur O, Zinzani P. 855 | a phase 3 randomized trial: duvelisib versus investigator choice (gemcitabine or bendamustine) in relapsed\/refractory nodal t-cell lymphoma with t-follicular helper phenotype. Hematol Oncol [Internet]. 2025;43(S3):43. Available from: https:\/\/doi.org\/10.1002\/hon.70096_855.","journal-title":"Hematol Oncol"},{"issue":"20","key":"985_CR135","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO-25-03120","volume":"44","author":"N Mehta-Shah","year":"2026","unstructured":"Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, et al. Duvelisib induces deep responses in peripheral T-cell lymphoma: final results of the phase II PRIMO trial of duvelisib in relapsed\/refractory peripheral T-cell lymphoma. J Clin Oncol [Internet]. 2026;44(20):1889\u201398. Available from: https:\/\/doi.org\/10.1200\/JCO-25-03120.","journal-title":"J Clin Oncol"},{"key":"985_CR136","doi-asserted-by":"publisher","unstructured":"Mehta-Shah N, Geyer SM, Barta SK, Amengual JE, Dockter T, Wright C, et al. Alliance A059102: a randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas. J Clin Oncol [Internet]. 2022;40(16_suppl):TPS7593\u20137593. Available from: https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.tps7593.","DOI":"10.1200\/jco.2022.40.16_suppl.tps7593"},{"issue":"16_suppl","key":"985_CR137","doi-asserted-by":"publisher","first-page":"7069","DOI":"10.1200\/JCO.2024.42.16_suppl.7069","volume":"42","author":"SP Iyer","year":"2024","unstructured":"Iyer SP, Jagadeesh D, Domingo-Domenech E, Benedetti F, Rodriguez Izquierdo A, Bouabdallah K, et al. Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: results from the phase 2 SGN35-032 study. JCO [Internet]. 2024;42(16_suppl):7069\u20137069. Available from: https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7069.","journal-title":"JCO"},{"key":"985_CR138","doi-asserted-by":"publisher","unstructured":"Iyer SP, Jagadeesh D, Domenech ED, Benedetti F, Izquierdo AR, Bouabdallah K, et al. TCL-955: frontline brentuximab vedotin and CHP in patients with peripheral T-cell lymphoma with <10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study. Clin Lymphoma Myeloma Leuk [Internet]. 2025;25:S874\u20135. Available from: https:\/\/doi.org\/10.1016\/S2152-2650(25)02517-0.","DOI":"10.1016\/S2152-2650(25)02517-0"},{"key":"985_CR139","doi-asserted-by":"publisher","unstructured":"Cwynarski K, Domingo Domenech E, Sidransky D, Bentur OS, Zinzani PL. A multicenter, open-label, phase 3, randomized controlled trial of duvelisib versus Investigator\u2019s choice of gemcitabine or bendamustine in patients with Relapsed\/Refractory nodal T cell lymphoma with T follicular helper phenotype. Blood [Internet]. 2024;144:.3074.1\u20133074.1. Available from: https:\/\/doi.org\/10.1182\/blood-2024-203290.","DOI":"10.1182\/blood-2024-203290"},{"issue":"Supplement 1","key":"985_CR140","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2022-156789","volume":"140","author":"J Dupuis","year":"2022","unstructured":"Dupuis J, Tsukasaki K, Bachy E, Morschhauser F, Cartron G, Fukuhara N, et al. Oral azacytidine in patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: final analysis of the oracle phase III study. Blood [Internet]. 2022;140(Supplement 1):2310\u201312. Available from: https:\/\/doi.org\/10.1182\/blood-2022-156789.","journal-title":"Blood"},{"key":"985_CR141","doi-asserted-by":"publisher","unstructured":"Starodub A, Gollerkeri A, De Savi C, Dey J, Agarwal S, Donohue S, et al. Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors. J Clin Oncol [Internet]. 2022;40(16_suppl):TPS3171\u20133171. Available from: https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.tps3171.","DOI":"10.1200\/jco.2022.40.16_suppl.tps3171"},{"issue":"2","key":"985_CR142","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jjco\/hyae144","volume":"55","author":"R Kita","year":"2025","unstructured":"Kita R, Shimada K, Machida R, Sekita T, Sasaki K, Ishitsuka K, et al. Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study). Jpn J Clin Oncol [Internet]. 2025;55(2):183\u201388. Available from: https:\/\/doi.org\/10.1093\/jjco\/hyae144.","journal-title":"Jpn J Clin Oncol"},{"issue":"37","key":"985_CR143","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene [Internet]. 2007;26(37):5420\u201332. Available from: https:\/\/doi.org\/10.1038\/sj.onc.1210610.","journal-title":"Oncogene"},{"issue":"3","key":"985_CR144","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer [Internet]. 2001;1(3):194\u2013202. Available from: https:\/\/doi.org\/10.1038\/35106079.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"985_CR145","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.2320","volume":"35","author":"B Pro","year":"2017","unstructured":"Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol [Internet]. 2017;35(4):914\u201317. Available from: https:\/\/doi.org\/10.1002\/hon.2320.","journal-title":"Hematol Oncol"},{"issue":"4","key":"985_CR146","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","volume":"131","author":"JE Amengual","year":"2018","unstructured":"Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood [Internet]. 2018;131(4):397\u2013407. Available from: https:\/\/doi.org\/10.1182\/blood-2017-09-806737.","journal-title":"Blood"},{"issue":"Supplement 1","key":"985_CR147","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-143252","volume":"136","author":"SP Iyer","year":"2020","unstructured":"Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, et al. A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL). Blood [Internet]. 2020;136(Supplement 1):40\u201341. Available from: https:\/\/doi.org\/10.1182\/blood-2020-143252.","journal-title":"Blood"},{"issue":"16","key":"985_CR148","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood [Internet]. 2021;137(16):2161\u201370. Available from: https:\/\/doi.org\/10.1182\/blood.2020009004.","journal-title":"Blood"},{"issue":"10","key":"985_CR149","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ajh.26288","volume":"96","author":"N Mehta-Shah","year":"2021","unstructured":"Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, et al. Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts. Am J Hematol [Internet]. 2021;96(10):1211\u201322. Available from: https:\/\/doi.org\/10.1002\/ajh.26288.","journal-title":"Am J Hematol"},{"key":"985_CR150","doi-asserted-by":"publisher","unstructured":"Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, et al. A phase 1 trial of alisertib and romidepsin for relapsed\/refractory aggressive B-cell and T-cell lymphomas. Haematologica [Internet]. 2020;105(1):e26\u20138. Available from: https:\/\/doi.org\/10.3324\/haematol.2019.220012.","DOI":"10.3324\/haematol.2019.220012"},{"issue":"9","key":"985_CR151","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","volume":"30","author":"SM Horwitz","year":"2024","unstructured":"Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, et al. Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nat Med [Internet]. 2024;30(9):2517\u201327. Available from: https:\/\/doi.org\/10.1038\/s41591-024-03076-6.","journal-title":"Nat Med"},{"key":"985_CR152","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2021-145851","volume":"138","author":"SP Iyer","year":"2021","unstructured":"Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, et al. Safety and efficacy of tenalisib given in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: final results from a phase I\/II open label multi-center study. Blood [Internet]. 2021;138:1365\u20131365. Available from: https:\/\/doi.org\/10.1182\/blood-2021-145851.","journal-title":"Blood"},{"issue":"3","key":"985_CR153","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol [Internet]. 2022;40(3):242\u201351. Available from: https:\/\/doi.org\/10.1200\/JCO.21.01815.","journal-title":"J Clin Oncol"},{"key":"985_CR154","unstructured":"Bristol Myers Squibb Statement on Istodax\u00ae (romidepsin). Relapsed\/Refractory peripheral T-cell lymphoma U.S. Indication [Internet]. [https:\/\/news.bms.com\/news\/details\/2021\/Bristol-Myers-Squibb-Statement-on-Istodax-romidepsin-Relapsed-Refractory-Peripheral-T-cell-Lymphoma-U.S.-Indication\/default.aspx. 2026 Jan 10]"},{"issue":"7","key":"985_CR155","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","volume":"16","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs [Internet]. 2007;16(7):1111\u201320. Available from: https:\/\/doi.org\/10.1517\/13543784.16.7.1111.","journal-title":"Expert Opin Investig Drugs"},{"issue":"21","key":"985_CR156","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol [Internet]. 2007;25(21):3109\u201315. Available from: https:\/\/doi.org\/10.1200\/JCO.2006.10.2434.","journal-title":"J Clin Oncol"},{"issue":"1","key":"985_CR157","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjh.12326","volume":"162","author":"Y Oki","year":"2013","unstructured":"Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, et al. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol [Internet]. 2013;162(1):138\u201341. Available from: https:\/\/doi.org\/10.1111\/bjh.12326.","journal-title":"Br J Haematol"},{"issue":"3","key":"985_CR158","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","volume":"93","author":"G Hopfinger","year":"2014","unstructured":"Hopfinger G, N\u00f6sslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial. Ann Hematol [Internet]. 2014;93(3):459\u201362. Available from: https:\/\/doi.org\/10.1007\/s00277-014-2009-0.","journal-title":"Ann Hematol"},{"issue":"2","key":"985_CR159","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/10428194.2019.1672052","volume":"61","author":"T Siddiqi","year":"2020","unstructured":"Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, et al. Phase 1 study of the Aurora kinase a inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma [Internet]. 2020;61(2):309\u201317. Available from: https:\/\/doi.org\/10.1080\/10428194.2019.1672052.","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"985_CR160","doi-asserted-by":"publisher","first-page":"29102","DOI":"10.18632\/oncotarget.8667","volume":"7","author":"M Gao","year":"2016","unstructured":"Gao M, Chen G, Wang H, Xie B, Hu L, Kong Y, et al. Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia\/lymphoma. Oncotarget [Internet]. 2016;7(20):29102\u201315. Available from: https:\/\/doi.org\/10.18632\/oncotarget.8667.","journal-title":"Oncotarget"},{"issue":"1","key":"985_CR161","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","volume":"10","author":"PB Johnston","year":"2021","unstructured":"Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, et al. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Exp Hematol Oncol [Internet]. 2021;10(1):15. Available from: https:\/\/doi.org\/10.1186\/s40164-021-00203-8.","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"985_CR162","doi-asserted-by":"publisher","first-page":"616","DOI":"10.21147\/j.issn.1000-9604.2021.05.08","volume":"33","author":"L Gui","year":"2021","unstructured":"Gui L, Cao J, Ji D, Zhang H, Fan Q, Zhu J, et al. Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. Chin J Cancer Res [Internet]. 2021;33(5):616\u201326. Available from: https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.05.08.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"985_CR163","doi-asserted-by":"publisher","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","volume":"18","author":"W Zhang","year":"2021","unstructured":"Zhang W, Su L, Liu L, Gao Y, Wang Q, Su H, et al. The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b\/2 study. Cancer Biol Med [Internet]. 2021;18(3):841\u201348. Available from: https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0413.","journal-title":"Cancer Biol Med"},{"issue":"5","key":"985_CR164","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.26499","volume":"97","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang M, Song W, Cai Q, Zhang L, Sun X, et al. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial. Am J Hematol [Internet]. 2022;97(5):623\u201329. Available from: https:\/\/doi.org\/10.1002\/ajh.26499.","journal-title":"Am J Hematol"},{"key":"985_CR165","doi-asserted-by":"publisher","unstructured":"Tan D, Phipps C, Hwang WYK, Tan SY, Yeap CH, Chan YH, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol [Internet]. 2015;2(8):e326\u201333. Available from: https:\/\/doi.org\/10.1016\/S2352-3026(15)00097-6.","DOI":"10.1016\/S2352-3026(15)00097-6"},{"key":"985_CR166","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1182\/blood-2021-152603","volume":"138","author":"BM Haverkos","year":"2021","unstructured":"Haverkos BM, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, et al. Nanatinostat (nstat) and valganciclovir (VGCV) in relapsed\/refractory (R\/R) epstein-barr virus-positive (EBV +) lymphomas: final results from the phase 1b\/2 VT3996-201 study. Blood [Internet]. 2021;138:623\u2013623. Available from: https:\/\/doi.org\/10.1182\/blood-2021-152603.","journal-title":"Blood"},{"issue":"3","key":"985_CR167","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/onco.13673","volume":"26","author":"JE Amengual","year":"2021","unstructured":"Amengual JE, Lue JK, Ma H, Lichtenstein R, Shah B, Cremers S, et al. First-in-class selective HDAC6 inhibitor (ACY-1215) has a highly favorable safety profile in patients with relapsed and refractory lymphoma. Oncologist [Internet]. 2021;26(3):184\u2013e366. Available from: https:\/\/doi.org\/10.1002\/onco.13673.","journal-title":"Oncologist"},{"issue":"5\u20136","key":"985_CR168","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10495-020-01607-3","volume":"25","author":"M Cosenza","year":"2020","unstructured":"Cosenza M, Civallero M, Marcheselli L, Sacchi S, Pozzi S. Citarinostat and momelotinib co-target HDAC6 and JAK2\/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Apoptosis [Internet]. 2020;25(5\u20136):370\u201387. Available from: https:\/\/doi.org\/10.1007\/s10495-020-01607-3.","journal-title":"Apoptosis"},{"issue":"16","key":"985_CR169","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","volume":"2","author":"TB Buus","year":"2018","unstructured":"Buus TB, Willerslev-Olsen A, Fredholm S, Bl\u00fcmel E, Nastasi C, Gluud M, et al. Single-cell heterogeneity in S\u00e9zary syndrome. Blood Adv [Internet]. 2018;2(16):2115\u201326. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2018022608.","journal-title":"Blood Adv"},{"key":"985_CR170","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ebiom.2019.07.053","volume":"46","author":"JM Andrews","year":"2019","unstructured":"Andrews JM, Schmidt JA, Carson KR, Musiek AC, Mehta-Shah N, Payton JE. Novel cell adhesion\/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. EBioMedicine [Internet]. 2019;46:170\u201383. Available from: https:\/\/doi.org\/10.1016\/j.ebiom.2019.07.053.","journal-title":"EBioMedicine"},{"issue":"8","key":"985_CR171","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1021\/acs.jmedchem.8b01597","volume":"62","author":"X Liang","year":"2019","unstructured":"Liang X, Zang J, Li X, Tang S, Huang M, Geng M, et al. Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies. J Med Chem [Internet]. 2019;62(8):3898\u2013923. Available from: https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01597.","journal-title":"J Med Chem"},{"issue":"10","key":"985_CR172","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome \u2014 biological and translational implications. Nat Rev Cancer [Internet]. 2011;11(10):726\u201334. Available from: https:\/\/doi.org\/10.1038\/nrc3130.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"985_CR173","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer [Internet]. 2006;106(8):1794\u2013803. Available from: https:\/\/doi.org\/10.1002\/cncr.21792.","journal-title":"Cancer"},{"issue":"15","key":"985_CR174","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L, R\u00fcter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European organisation for research and treatment of Cancer leukemia group and the German MDS study group. J Clin Oncol [Internet]. 2011;29(15):1987\u201396. Available from: https:\/\/doi.org\/10.1200\/JCO.2010.30.9245.","journal-title":"J Clin Oncol"},{"issue":"4","key":"985_CR175","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/bf02135399","volume":"20","author":"F Sorm","year":"1964","unstructured":"Sorm F, P\u00edskala A, Cih\u00e1k A, Vesel\u00fd J. 5-azacytidine, a new, highly effective cancerostatic. Experientia [Internet]. 1964;20(4):202\u201303. Available from: https:\/\/doi.org\/10.1007\/bf02135399.","journal-title":"Experientia"},{"issue":"11","key":"985_CR176","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1182\/blood.V110.11.817.817","volume":"110","author":"P Fenaux","year":"2007","unstructured":"Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood [Internet]. 2007;110(11):817\u2013817. Available from: https:\/\/doi.org\/10.1182\/blood.V110.11.817.817.","journal-title":"Blood"},{"issue":"7","key":"985_CR177","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med [Internet]. 2020;383(7):617\u201329. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"4","key":"985_CR178","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol [Internet]. 2024;99(4):615\u201324. Available from: https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"issue":"18","key":"985_CR179","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1182\/blood.2022018254","volume":"141","author":"J Ruan","year":"2023","unstructured":"Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood [Internet]. 2023;141(18):2194\u2013205. Available from: https:\/\/doi.org\/10.1182\/blood.2022018254.","journal-title":"Blood"},{"key":"985_CR180","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1182\/blood-2025-780","volume":"146","author":"T Xu","year":"2025","unstructured":"Xu T, Yang Q, Wu D, Li C. A prospective clinical study on the combination of anti-PD1 monoclonal antibody with lenalidomide and azacitidine for the treatment of relapsed\/refractory peripheral T-cell lymphoma. Blood [Internet]. 2025;146:780\u2013780. Available from: https:\/\/doi.org\/10.1182\/blood-2025-780.","journal-title":"Blood"},{"key":"985_CR181","doi-asserted-by":"publisher","first-page":"1410638","DOI":"10.3389\/fimmu.2024.1410638","volume":"15","author":"L Ricard","year":"2024","unstructured":"Ricard L, Cervera P, Stocker N, Corre E, Van de Wyngaert Z, Banet A, et al. A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed\/refractory AITL. Front Immunol [Internet]. 2024;15:1410638. Available from: https:\/\/doi.org\/10.3389\/fimmu.2024.1410638.","journal-title":"Front Immunol"},{"issue":"2","key":"985_CR182","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/aps.2013.161","volume":"35","author":"J-Z Tan","year":"2014","unstructured":"Tan J-Z, Yan Y, Wang X-X, Jiang Y, Xu HE. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin [Internet]. 2014;35(2):161\u201374. Available from: https:\/\/doi.org\/10.1038\/aps.2013.161.","journal-title":"Acta Pharmacol Sin"},{"issue":"1\u20132","key":"985_CR183","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","volume":"647","author":"JA Simon","year":"2008","unstructured":"Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res [Internet]. 2008;647(1\u20132):21\u201329. Available from: https:\/\/doi.org\/10.1016\/j.mrfmmm.2008.07.010.","journal-title":"Mutat Res"},{"issue":"12","key":"985_CR184","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/biomedicines9121842","volume":"9","author":"FL Sch\u00fcmann","year":"2021","unstructured":"Sch\u00fcmann FL, Gro\u00df E, Bauer M, Rohde C, Sandmann S, Terziev D, et al. Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-cell lymphomas. Biomedicines [Internet]. 2021;9(12):1842. Available from: https:\/\/doi.org\/10.3390\/biomedicines9121842.","journal-title":"Biomedicines"},{"issue":"8","key":"985_CR185","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep [Internet]. 2019;29(8):2321\u201337.e7. Available from: https:\/\/doi.org\/10.1016\/j.celrep.2019.10.083.","journal-title":"Cell Rep"},{"issue":"16","key":"985_CR186","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Valemetostat tosilate: first approval. Drugs [Internet]. 2022;82(16):1621\u201327. Available from: https:\/\/doi.org\/10.1007\/s40265-022-01800-5.","journal-title":"Drugs"},{"issue":"7","key":"985_CR187","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","volume":"9","author":"Y Rochman","year":"2009","unstructured":"Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by \u03b3c family cytokines. Nat Rev Immunol [Internet]. 2009;9(7):480\u201390. Available from: https:\/\/doi.org\/10.1038\/nri2580.","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"985_CR188","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1182\/blood-2011-09-379958","volume":"119","author":"M Porcu","year":"2012","unstructured":"Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tartaglia M, et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood [Internet]. 2012;119(19):4476\u201379. Available from: https:\/\/doi.org\/10.1182\/blood-2011-09-379958.","journal-title":"Blood"},{"issue":"11","key":"985_CR189","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1016\/j.ajpath.2015.07.021","volume":"185","author":"S Jain","year":"2015","unstructured":"Jain S, Chen J, Nicolae A, Wang H, Shin D-M, Adkins EB, et al. IL-21\u2013driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-Cell lymphoma. Am J Pathol [Internet]. 2015;185(11):3102\u201314. Available from: https:\/\/doi.org\/10.1016\/j.ajpath.2015.07.021.","journal-title":"Am J Pathol"},{"issue":"6","key":"985_CR190","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm1249","volume":"11","author":"R Chiarle","year":"2005","unstructured":"Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med [Internet]. 2005;11(6):623\u201329. Available from: https:\/\/doi.org\/10.1038\/nm1249.","journal-title":"Nat Med"},{"issue":"15","key":"985_CR191","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood [Internet]. 2012;120(15):3048\u201357. Available from: https:\/\/doi.org\/10.1182\/blood-2012-06-435297.","journal-title":"Blood"},{"issue":"2","key":"985_CR192","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/leu.2013.157","volume":"28","author":"A Bouchekioua","year":"2014","unstructured":"Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardin A, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia [Internet]. 2014;28(2):338\u201348. Available from: https:\/\/doi.org\/10.1038\/leu.2013.157.","journal-title":"Leukemia"},{"issue":"9","key":"985_CR193","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/leu.2009.91","volume":"23","author":"P Coppo","year":"2009","unstructured":"Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK\/T-cell lymphoma. Leukemia [Internet]. 2009;23(9):1667\u201378. Available from: https:\/\/doi.org\/10.1038\/leu.2009.91.","journal-title":"Leukemia"},{"issue":"5220","key":"985_CR194","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.7604283","volume":"269","author":"TS Migone","year":"1995","unstructured":"Migone TS, Lin JX, Cereseto A, Mulloy JC, O\u2019Shea JJ, Franchini G, et al. Constitutively activated jak-STAT pathway in T cells transformed with HTLV-I. Science [Internet]. 1995;269(5220):79\u201381. Available from: https:\/\/doi.org\/10.1126\/science.7604283.","journal-title":"Science"},{"issue":"6","key":"985_CR195","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/10428194.2025.2455489","volume":"66","author":"SM Horwitz","year":"2025","unstructured":"Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, et al. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase\/janus kinase inhibitor, in relapsed\/refractory peripheral T-cell lymphoma. Leuk Lymphoma [Internet]. 2025;66(6):1100\u201310. Available from: https:\/\/doi.org\/10.1080\/10428194.2025.2455489.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"985_CR196","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer [Internet]. 2009;9(8):550\u201362. Available from: https:\/\/doi.org\/10.1038\/nrc2664.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"985_CR197","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2011-07-366203","volume":"119","author":"R Polak","year":"2012","unstructured":"Polak R, Buitenhuis M. The PI3K\/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood [Internet]. 2012;119(4):911\u201323. Available from: https:\/\/doi.org\/10.1182\/blood-2011-07-366203.","journal-title":"Blood"},{"issue":"1","key":"985_CR198","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bjh.13065","volume":"167","author":"JS Blachly","year":"2014","unstructured":"Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol [Internet]. 2014;167(1):19\u201332. Available from: https:\/\/doi.org\/10.1111\/bjh.13065.","journal-title":"Br J Haematol"},{"issue":"4","key":"985_CR199","first-page":"2465","volume":"35","author":"JY Hong","year":"2015","unstructured":"Hong JY, Hong ME, Choi MK, Chang W, Do I-G, Jo J-S, et al. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Res [Internet]. 2015;35(4):2465\u201374. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25862915.","journal-title":"Anticancer Res"},{"issue":"11","key":"985_CR200","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med [Internet]. 2014;370(11):1008\u201318. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1314583.","journal-title":"N Engl J Med"},{"issue":"10","key":"985_CR201","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann Oncol [Internet]. 2016;27(10):1928\u201340. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdw282.","journal-title":"Ann Oncol"},{"issue":"8","key":"985_CR202","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3390\/cancers12082293","volume":"12","author":"A Huen","year":"2020","unstructured":"Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, et al. Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory T-Cell lymphoma. Cancers (Basel) [Internet]. 2020;12(8):2293. Available from: https:\/\/doi.org\/10.3390\/cancers12082293.","journal-title":"Cancers (Basel)"},{"key":"985_CR203","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3324\/haematol.2022.281875","volume":"109","author":"SP Iyer","year":"2023","unstructured":"Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, et al. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study. Haematologica [Internet]. 2023;109:209\u201319. Available from: https:\/\/doi.org\/10.3324\/haematol.2022.281875.","journal-title":"Haematologica"},{"issue":"8","key":"985_CR204","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood [Internet]. 2018;131(8):888\u201398. Available from: https:\/\/doi.org\/10.1182\/blood-2017-08-802470.","journal-title":"Blood"},{"issue":"2","key":"985_CR205","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/hon.3164_367","volume":"41","author":"N Mehta-Shah","year":"2023","unstructured":"Mehta-Shah N, Jacobsen ED, Zinzani PL, Zain J, Mead M, Casulo C, et al. 17th international conference on malignant lymphoma, Palazzo dei congressi, Lugano, Switzerland, 13 \u2013 17 June, 2023. Hematol Oncol [Internet]. 2023;41(2):499\u2013500. Available from: https:\/\/doi.org\/10.1002\/hon.3164_367.","journal-title":"Hematol Oncol"},{"key":"985_CR206","doi-asserted-by":"publisher","unstructured":"NCCN Guidelines\u00ae Updates: T-Cell Lymphomas. J Natl Compr Canc Netw [Internet]. 2022;20(3):xxxv - xxxvi. Available from: https:\/\/doi.org\/10.6004\/jnccn.2022.203glup.","DOI":"10.6004\/jnccn.2022.203glup"},{"issue":"5151","key":"985_CR207","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science [Internet]. 1994;263(5151):1281\u201384. Available from: https:\/\/doi.org\/10.1126\/science.8122112.","journal-title":"Science"},{"issue":"11","key":"985_CR208","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","volume":"93","author":"RD Gascoyne","year":"1999","unstructured":"Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood [Internet]. 1999;93(11):3913\u201321. Available from: https:\/\/doi.org\/10.1182\/blood.V93.11.3913.","journal-title":"Blood"},{"issue":"4","key":"985_CR209","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.onc.1200849","volume":"14","author":"T Iwahara","year":"1997","unstructured":"Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene [Internet]. 1997;14(4):439\u201349. Available from: https:\/\/doi.org\/10.1038\/sj.onc.1200849.","journal-title":"Oncogene"},{"issue":"4","key":"985_CR210","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood.v89.4.1394","volume":"89","author":"K Pulford","year":"1997","unstructured":"Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood [Internet]. 1997;89(4):1394\u2013404. Available from: https:\/\/doi.org\/10.1182\/blood.v89.4.1394.","journal-title":"Blood"},{"key":"985_CR211","doi-asserted-by":"publisher","unstructured":"Merino M, Kasamon Y, Li H, Ma L, Leong R, Zhou J, et al. FDA approval summary: crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. Pediatr Blood Cancer [Internet]. 2022;69(8):e29602. Available from: https:\/\/doi.org\/10.1002\/pbc.29602.","DOI":"10.1002\/pbc.29602"},{"issue":"28","key":"985_CR212","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Moss\u00e9","year":"2017","unstructured":"Moss\u00e9 YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\u2019s oncology group study. J Clin Oncol [Internet]. 2017;35(28):3215\u201321. Available from: https:\/\/doi.org\/10.1200\/JCO.2017.73.4830.","journal-title":"J Clin Oncol"},{"issue":"6","key":"985_CR213","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Moss\u00e9","year":"2013","unstructured":"Moss\u00e9 YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s oncology group phase 1 consortium study. The Lancet Oncol [Internet]. 2013;14(6):472\u201380. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(13)70095-0.","journal-title":"The Lancet Oncol"},{"issue":"12","key":"985_CR214","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","volume":"22","author":"M Fischer","year":"2021","unstructured":"Fischer M, Moreno L, Ziegler DS, Marshall LV, Zwaan CM, Irwin MS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. The Lancet Oncol [Internet]. 2021;22(12):1764\u201376. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(21)00536-2.","journal-title":"The Lancet Oncol"},{"issue":"12","key":"985_CR215","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1111\/cas.14671","volume":"111","author":"R Fukano","year":"2020","unstructured":"Fukano R, Mori T, Sekimizu M, Choi I, Kada A, Saito AM, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial. Cancer Sci [Internet]. 2020;111(12):4540\u201347. Available from: https:\/\/doi.org\/10.1111\/cas.14671.","journal-title":"Cancer Sci"},{"key":"985_CR216","doi-asserted-by":"publisher","first-page":"112984","DOI":"10.1016\/j.ejca.2023.112984","volume":"191","author":"L Brugi\u00e8res","year":"2023","unstructured":"Brugi\u00e8res L, Cozic N, Houot R, Rigaud C, Sibon D, Arfi-Rouche J, et al. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS\u00e9-crizotinib trial. Eur J Cancer [Internet]. 2023;191:112984. Available from: https:\/\/doi.org\/10.1016\/j.ejca.2023.112984.","journal-title":"Eur J Cancer"},{"key":"985_CR217","doi-asserted-by":"publisher","unstructured":"Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, Chemoresistant anaplastic lymphoma kinase\u2013positive lymphoma patients. J Natl Cancer Inst [Internet]. 2014;106(2):djt378. Available from: https:\/\/doi.org\/10.1093\/jnci\/djt378.","DOI":"10.1093\/jnci\/djt378"},{"issue":"2","key":"985_CR218","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/1541-7786.MCR-12-0569","volume":"11","author":"M Ceccon","year":"2013","unstructured":"Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors. Mol Cancer Res [Internet]. 2013;11(2):122\u201332. Available from: https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0569.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"985_CR219","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0092-8674(90)90242-7","volume":"62","author":"Y Reiss","year":"1990","unstructured":"Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21 farnesyl: protein transferase by cys-AAX tetrapeptides. Cell [Internet]. 1990;62(1):81\u201388. Available from: https:\/\/doi.org\/10.1016\/0092-8674(90)90242-7.","journal-title":"Cell"},{"issue":"5","key":"985_CR220","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1039\/c7md00030h","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Yao X, Huang J. New tricks for human farnesyltransferase inhibitor: cancer and beyond. Med. Chem. Commun [Internet]. 2017;8(5):841\u201354. Available from: https:\/\/doi.org\/10.1039\/c7md00030h.","journal-title":"Med. Chem. Commun"},{"issue":"10","key":"985_CR221","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1091\/mbc.E14-11-1560","volume":"26","author":"AJ Holland","year":"2015","unstructured":"Holland AJ, Reis RM, Niessen S, Pereira C, Andres DA, Spielmann HP, et al. Preventing farnesylation of the dynein adaptor spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors. Mol Biol Cell [Internet]. 2015;26(10):1845\u201356. Available from: https:\/\/doi.org\/10.1091\/mbc.E14-11-1560.","journal-title":"Mol Biol Cell"},{"issue":"17","key":"985_CR222","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1182\/bloodadvances.2024012806","volume":"8","author":"T Witzig","year":"2024","unstructured":"Witzig T, Sokol L, Kim WS, de la Cruz Vicente F, Mart\u00edn Garc\u00eda-Sancho A, Advani R, et al. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma. Blood Adv [Internet]. 2024;8(17):4581\u201392. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2024012806.","journal-title":"Blood Adv"},{"issue":"6165","key":"985_CR223","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science [Internet]. 2013;342(6165):1432\u201333. Available from: https:\/\/doi.org\/10.1126\/science.342.6165.1432.","journal-title":"Science"},{"key":"985_CR224","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","volume":"14","author":"WB Coley II","year":"1891","unstructured":"Coley WB II. Contribution to the knowledge of sarcoma. Ann SurgAnnals Surg [Internet]. 1891;14:199\u2013220. Available from: https:\/\/doi.org\/10.1097\/00000658-189112000-00015.","journal-title":"Ann SurgAnnals Surg"},{"issue":"5256","key":"985_CR225","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science [Internet]. 1996;271(5256):1734\u201336. Available from: https:\/\/doi.org\/10.1126\/science.271.5256.1734.","journal-title":"Science"},{"key":"985_CR226","unstructured":"Rituximab Product Approval Information - Licensing Action [Internet]. [https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/1997\/ritugen112697l.htm. 2026 Feb 1]"},{"issue":"24","key":"985_CR227","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","volume":"25","author":"YL Kasamon","year":"2019","unstructured":"Kasamon YL, Chen H, de Claro RA, Nie L, Ye J, Blumenthal GM, et al. FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and S\u00e9zary syndrome. Clin Cancer Res [Internet]. 2019;25(24):7275\u201380. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2030.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"985_CR228","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","volume":"72","author":"JM Subramaniam","year":"2012","unstructured":"Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval: first global approval. Drugs [Internet]. 2012;72(9):1293\u201398. Available from: https:\/\/doi.org\/10.2165\/11631090-000000000-00000.","journal-title":"Drugs"},{"issue":"10","key":"985_CR229","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/cas.13343","volume":"108","author":"T Ishida","year":"2017","unstructured":"Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, et al. Mogamulizumab for relapsed adult T-cell leukemia\u2013lymphoma: updated follow-up analysis of phase I and II studies. Cancer Sci [Internet]. 2017;108(10):2022\u201329. Available from: https:\/\/doi.org\/10.1111\/cas.13343.","journal-title":"Cancer Sci"},{"issue":"5","key":"985_CR230","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol [Internet]. 2015;169(5):672\u201382. Available from: https:\/\/doi.org\/10.1111\/bjh.13338.","journal-title":"Br J Haematol"},{"issue":"16","key":"985_CR231","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","volume":"10","author":"T Ishida","year":"2004","unstructured":"Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res [Internet]. 2004;10(16):5494\u2013500. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0371.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"985_CR232","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.V96.2.685.014k26_685_690","volume":"96","author":"D Jones","year":"2000","unstructured":"Jones D, O\u2019Hara C, Kraus MD, Perez\u2013Atayde AR, Shahsafaei A, Wu L, et al. Expression pattern of T-cell\u2013associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-hodgkin lymphoma. Blood [Internet]. 2000;96(2):685\u201390. Available from: https:\/\/doi.org\/10.1182\/blood.V96.2.685.014k26_685_690.","journal-title":"Blood"},{"issue":"3","key":"985_CR233","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","volume":"120","author":"C Dearden","year":"2012","unstructured":"Dearden C. How I treat prolymphocytic leukemia. Blood [Internet]. 2012;120(3):538\u201351. Available from: https:\/\/doi.org\/10.1182\/blood-2012-01-380139.","journal-title":"Blood"},{"key":"985_CR234","doi-asserted-by":"publisher","first-page":"781479","DOI":"10.3389\/fonc.2022.781479","volume":"12","author":"I Varadarajan","year":"2022","unstructured":"Varadarajan I, Ballen K. Advances in cellular therapy for T-cell prolymphocytic leukemia. Front Oncol [Internet]. 2022;12:781479. Available from: https:\/\/doi.org\/10.3389\/fonc.2022.781479.","journal-title":"Front Oncol"},{"issue":"7","key":"985_CR235","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie innovative nei linfomi) prospective multicenter trial. Blood [Internet]. 2007;110(7):2316\u201323. Available from: https:\/\/doi.org\/10.1182\/blood-2007-02-074641.","journal-title":"Blood"},{"issue":"8","key":"985_CR236","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1080\/10428194.2018.1562184","volume":"60","author":"J Roswarski","year":"2019","unstructured":"Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, et al. Phase 1\/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Leuk Lymphoma [Internet]. 2019;60(8):2062\u201366. Available from: https:\/\/doi.org\/10.1080\/10428194.2018.1562184.","journal-title":"Leuk Lymphoma"},{"key":"985_CR237","doi-asserted-by":"publisher","unstructured":"Zaja F, Tabanelli V, Agostinelli C, Calleri A, Chiappella A, Varettoni M, et al. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: possible biomarkers for novel targeted therapies? Am J Hematol [Internet]. 2017;92(1):E1\u20132. Available from: https:\/\/doi.org\/10.1002\/ajh.24571.","DOI":"10.1002\/ajh.24571"},{"key":"985_CR238","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1182\/blood.V130.Suppl_1.2814.2814","volume":"130","author":"N Mustafa","year":"2017","unstructured":"Mustafa N, Nee HFA, Lee XT, Jin W, Yu Y, Chen Y, et al. Daratumumab efficiently targets NK\/T cell lymphoma with high CD38 expression. Blood [Internet]. 2017;130:2814\u20132814. Available from: https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.2814.2814.","journal-title":"Blood"},{"issue":"1","key":"985_CR239","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","volume":"14","author":"H Huang","year":"2021","unstructured":"Huang H, Zhu J, Yao M, Kim TM, Yoon DH, Cho S-G, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J Hematol Oncol [Internet]. 2021;14(1):25. Available from: https:\/\/doi.org\/10.1186\/s13045-020-01020-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"985_CR240","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjh.14770","volume":"179","author":"MJ Flynn","year":"2017","unstructured":"Flynn MJ, Hartley JA. The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Br J Haematol [Internet]. 2017;179(1):20\u201335. Available from: https:\/\/doi.org\/10.1111\/bjh.14770.","journal-title":"Br J Haematol"},{"issue":"1","key":"985_CR241","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1309\/AJCP6Q7QMUVGMVMF","volume":"132","author":"G Gualco","year":"2009","unstructured":"Gualco G, Chioato L, Weiss LM, Harrington WJ Jr, Bacchi CE. Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol [Internet]. 2009;132(1):28\u201333. Available from: https:\/\/doi.org\/10.1309\/AJCP6Q7QMUVGMVMF.","journal-title":"Am J Clin Pathol"},{"issue":"18","key":"985_CR242","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1182\/bloodadvances.2023012497","volume":"8","author":"J Zain","year":"2024","unstructured":"Zain J, Tsai N-C, Palmer J, Simpson J, Adhikarla V, Bading JR, et al. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in peripheral T-cell lymphoma. Blood Adv [Internet]. 2024;8(18):4812\u201322. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2023012497.","journal-title":"Blood Adv"},{"issue":"9","key":"985_CR243","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","volume":"133","author":"G Albayrak","year":"2025","unstructured":"Albayrak G, Wan PK-T, Fisher K, Seymour LW. T cell engagers: expanding horizons in oncology and beyond. Br J Cancer [Internet]. 2025;133(9):1241\u201349. Available from: https:\/\/doi.org\/10.1038\/s41416-025-03125-y.","journal-title":"Br J Cancer"},{"issue":"11","key":"985_CR244","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrd4779","volume":"14","author":"A Mullard","year":"2015","unstructured":"Mullard A. FDA approves first immunotherapy combo. Nat Rev Drug Discov [Internet]. 2015;14(11):739\u20137. Available from: https:\/\/doi.org\/10.1038\/nrd4779.","journal-title":"Nat Rev Drug Discov"},{"key":"985_CR245","doi-asserted-by":"publisher","unstructured":"Guidi L, Etessami J, Valenza C, Valdivia A, Meric-Bernstam F, Felip E, et al. Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances. Am Soc Clin Oncol Educ Book [Internet]. 2025;45(3):e473148. Available from: https:\/\/doi.org\/10.1200\/EDBK-25-473148.","DOI":"10.1200\/EDBK-25-473148"},{"key":"985_CR246","doi-asserted-by":"publisher","unstructured":"Paul S, Pearlman AH, Douglass J, Mog BJ, Hsiue EH-C, Hwang MS, et al. TCR \u03b2 chain\u2013directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med [Internet]. 2021;13(584):eabd3595. Available from: https:\/\/doi.org\/10.1126\/scitranslmed.abd3595.","DOI":"10.1126\/scitranslmed.abd3595"},{"issue":"26","key":"985_CR247","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood [Internet]. 2015;125(26):4024\u201331. Available from: https:\/\/doi.org\/10.1182\/blood-2014-12-614636.","journal-title":"Blood"},{"issue":"Supplement 1","key":"985_CR248","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140096","volume":"136","author":"A Sawas","year":"2020","unstructured":"Sawas A, Chen P-H, Lipschitz M, Rodig S, Vlad G. Title: clinical and biological evaluation of the novel CD30\/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with cutaneous presentation: a biomarker phase Ib\/IIa study (NCT03192202). Blood [Internet]. 2020;136(Supplement 1):25\u201326. Available from: https:\/\/doi.org\/10.1182\/blood-2020-140096.","journal-title":"Blood"},{"issue":"1","key":"985_CR249","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/1078-0432.CCR-24-1913","volume":"31","author":"WS Kim","year":"2025","unstructured":"Kim WS, Shortt J, Zinzani PL, Mikhailova N, Radeski D, Ribrag V, et al. A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas. Clin Cancer Res [Internet]. 2025;31(1):65\u201373. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1913.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"985_CR250","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med [Internet]. 2025;31(6):1987\u201393. Available from: https:\/\/doi.org\/10.1038\/s41591-025-03640-8.","journal-title":"Nat Med"},{"key":"985_CR251","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1182\/blood-2023-174250","volume":"142","author":"A Moskowitz","year":"2023","unstructured":"Moskowitz A, Harstrick A, Emig M, Overesch A, Pinto S, Ravenstijn P, et al. AFM13 in combination with allogeneic natural killer cells (AB-101) in relapsed or refractory Hodgkin lymphoma and CD30 + peripheral T-cell lymphoma: a phase 2 study (LuminICE). Blood [Internet]. 2023;142:4855\u20134855. Available from: https:\/\/doi.org\/10.1182\/blood-2023-174250.","journal-title":"Blood"},{"issue":"16_suppl","key":"985_CR252","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/jco.2025.43.16_suppl.7008","volume":"43","author":"JE Maakaron","year":"2025","unstructured":"Maakaron JE, Feldman TA, Fehniger TA, Shah GL, Mehta A, Modi D, et al. Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical hodgkin lymphoma (LuminICE-203). J Clin Oncol [Internet]. 2025;43(16_suppl):7008\u20137008. Available from: https:\/\/doi.org\/10.1200\/jco.2025.43.16_suppl.7008.","journal-title":"J Clin Oncol"},{"key":"985_CR253","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.1158\/1538-7445.AM2025-7324","volume":"85","author":"N Tateshita","year":"2025","unstructured":"Tateshita N, Watanabe N, Shimbo T, Morimoto A, Takeda K, Tanihiro T. Abstract 7324: ONO-4685: a novel PD-1\/CD3 bispecific T-cell engager (TCE) for the treatment of T-cell malignancies. Cancer Res [Internet]. 2025;85:7324\u20137324. Available from: https:\/\/doi.org\/10.1158\/1538-7445.AM2025-7324.","journal-title":"Cancer Res"},{"key":"985_CR254","unstructured":"Approved Cellular and Gene Therapy Products [Internet]. U.S. Food and Drug Administration. FDA. 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. 2026 Feb 7"},{"issue":"4","key":"985_CR255","doi-asserted-by":"publisher","first-page":"93","DOI":"10.46989\/001c.124277","volume":"6","author":"ST Bhaskar","year":"2024","unstructured":"Bhaskar ST, Dholaria B, Savani BN, Sengsayadeth S, Oluwole O. Overview of approved CAR-T products and utility in clinical practice. Clin Hematol Int [Internet]. 2024;6(4):93\u201399. Available from: https:\/\/doi.org\/10.46989\/001c.124277.","journal-title":"Clin Hematol Int"},{"issue":"10","key":"985_CR256","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0145-2126(90)90176-a","volume":"14","author":"H Osada","year":"1990","unstructured":"Osada H, Emi N, Ueda R, Seto M, Koike K, Suchi T, et al. Genuine CD7 expression in acute leukemia and lymphoblastic lymphoma. Leukemia Res [Internet]. 1990;14(10):869\u201377. Available from: https:\/\/doi.org\/10.1016\/0145-2126(90)90176-a.","journal-title":"Leukemia Res"},{"issue":"4","key":"985_CR257","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1046\/j.1365-2141.1996.d01-1720.x","volume":"93","author":"L Ginaldi","year":"1996","unstructured":"Ginaldi L, Matutes E, Farahat N, De Martinis M, Morilla R, Catovsky D. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol [Internet]. 1996;93(4):921\u201327. Available from: https:\/\/doi.org\/10.1046\/j.1365-2141.1996.d01-1720.x.","journal-title":"Br J Haematol"},{"issue":"25","key":"985_CR258","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, et al. Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies. Blood [Internet]. 2022;140(25):2684\u201396. Available from: https:\/\/doi.org\/10.1182\/blood.2021015020.","journal-title":"Blood"},{"issue":"4","key":"985_CR259","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood.2021014498","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood [Internet]. 2022;140(4):321\u201334. Available from: https:\/\/doi.org\/10.1182\/blood.2021014498.","journal-title":"Blood"},{"issue":"25","key":"985_CR260","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1182\/blood.2022017935","volume":"140","author":"M Themeli","year":"2022","unstructured":"Themeli M. Selecting CD7\u2212 T cells for CAR T-cell therapy. Blood [Internet]. 2022;140(25):2652\u201353. Available from: https:\/\/doi.org\/10.1182\/blood.2022017935.","journal-title":"Blood"},{"key":"985_CR261","doi-asserted-by":"publisher","unstructured":"Ghobadi A, Aldoss I, Maude S, Bhojwani D, Wayne A, Bajel A, et al. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma: a phase 1\/2 trial. Res Sq [Internet]. 2024, Available from: https:\/\/doi.org\/10.21203\/rs.3.rs-4676375\/v1.","DOI":"10.21203\/rs.3.rs-4676375\/v1"},{"issue":"13","key":"985_CR262","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin Cancer Res [Internet]. 2022;28(13):2830\u201343. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4097.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"985_CR263","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat Med [Internet]. 2024;30(12):3687\u201396. Available from: https:\/\/doi.org\/10.1038\/s41591-024-03228-8.","journal-title":"Nat Med"},{"issue":"16","key":"985_CR264","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med [Internet]. 2024;390(16):1467\u201380. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2313812.","journal-title":"N Engl J Med"},{"issue":"1","key":"985_CR265","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-023-01494-5","volume":"8","author":"S Schwarz","year":"2023","unstructured":"Schwarz S, Linnebacher M. CD5: from antiquated T cell marker to immunotherapy\u2019s new hope. Sig Transduct Target Ther [Internet]. 2023;8(1):216. Available from: https:\/\/doi.org\/10.1038\/s41392-023-01494-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"19","key":"985_CR266","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.3390\/cancers16193430","volume":"16","author":"O Elghawy","year":"2024","unstructured":"Elghawy O, Cao M, Xu J, Landsburg DJ, Svoboda J, Nasta SD, et al. Prevalence and prognostication of CD5+ mature T-cell lymphomas. Cancers (Basel) [Internet]. 2024;16(19):3430. Available from: https:\/\/doi.org\/10.3390\/cancers16193430.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"985_CR267","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood.2023022204","volume":"143","author":"LC Hill","year":"2024","unstructured":"Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas. Blood [Internet]. 2024;143(13):1231\u201341. Available from: https:\/\/doi.org\/10.1182\/blood.2023022204.","journal-title":"Blood"},{"issue":"1","key":"985_CR268","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","volume":"14","author":"H Lin","year":"2024","unstructured":"Lin H, Cheng J, Zhu L, Zeng Y, Dai Z, Zhang Y, et al. Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control. Blood Cancer J [Internet]. 2024;14(1):98. Available from: https:\/\/doi.org\/10.1038\/s41408-024-01082-y.","journal-title":"Blood Cancer J"},{"issue":"12","key":"985_CR269","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat Med [Internet]. 2017;23(12):1416\u201323. Available from: https:\/\/doi.org\/10.1038\/nm.4444.","journal-title":"Nat Med"},{"issue":"1","key":"985_CR270","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","volume":"31","author":"K Cwynarski","year":"2025","unstructured":"Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine DA, Balasubramaniam N, et al. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial. Nat Med [Internet]. 2025;31(1):137\u201343. Available from: https:\/\/doi.org\/10.1038\/s41591-024-03326-7.","journal-title":"Nat Med"},{"issue":"1","key":"985_CR271","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","volume":"10","author":"JMR Pierce","year":"2017","unstructured":"Pierce JMR, Mehta A. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Rev Hematol [Internet]. 2017;10(1):29\u201337. Available from: https:\/\/doi.org\/10.1080\/17474086.2017.1270202.","journal-title":"Expert Rev Hematol"},{"issue":"32","key":"985_CR272","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu M-F, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol [Internet]. 2020;38(32):3794\u2013804. Available from: https:\/\/doi.org\/10.1200\/JCO.20.01342.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"985_CR273","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.1182\/blood-2022-158869","volume":"140","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Flinn IW, Mei M, Riedell PA, Armand P, Grover NS, et al. Updated results and correlative analysis: autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT trial). Blood [Internet]. 2022;140(Supplement 1):7496\u201397. Available from: https:\/\/doi.org\/10.1182\/blood-2022-158869.","journal-title":"Blood"},{"key":"985_CR274","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2022-167504","volume":"140","author":"ACC Caballero Gonzalez","year":"2022","unstructured":"Caballero Gonzalez ACC, Escrib\u00e0-Garc\u00eda L, Montserrat R, Escudero-L\u00f3pez E, Pujol-Fern\u00e1ndez P, Ujald\u00f3n-Mir\u00f3 C, et al. Phase 1 clinical trial of memory-enriched academic HSP-CAR30 for the treatment of relapsed\/refractory hodgkin lymphoma and CD30+ T-cell lymphoma: clinical and biological studies. Blood [Internet]. 2022;140:405\u201307. Available from: https:\/\/doi.org\/10.1182\/blood-2022-167504.","journal-title":"Blood"},{"issue":"3","key":"985_CR275","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv [Internet]. 2024;8(3):802\u201314. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2023011470.","journal-title":"Blood Adv"},{"issue":"9","key":"985_CR276","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes. J Clin Invest [Internet]. 2017;127(9):3462\u201371. Available from: https:\/\/doi.org\/10.1172\/JCI94306.","journal-title":"J Clin Invest"},{"issue":"2","key":"985_CR277","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0165-2478(96)02693-4","volume":"55","author":"D Brugnoni","year":"1997","unstructured":"Brugnoni D, Air\u00f2 P, Marino R, Notarangelo LD, van Lier RW, Cattaneo R. CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation. Immunol Lett [Internet]. 1997;55(2):99\u2013104. Available from: https:\/\/doi.org\/10.1016\/s0165-2478(96)02693-4.","journal-title":"Immunol Lett"},{"key":"985_CR278","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1158\/1538-7445.AM2015-1686","volume":"75","author":"KW Wood","year":"2015","unstructured":"Wood KW, Gartner EM, Jonas M, Ryan M, Kennedy DA. Abstract 1686: CD70 as a target in non-Hodgkin lymphoma (NHL) and renal cell carcinoma (RCC). Cancer Res [Internet]. 2015;75:1686\u20131686. Available from: https:\/\/doi.org\/10.1158\/1538-7445.AM2015-1686. 2026 Feb 13.","journal-title":"Cancer Res"},{"key":"985_CR279","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1182\/blood-2021-146990","volume":"138","author":"ML Marques-Piubelli","year":"2021","unstructured":"Marques-Piubelli ML, Solis Soto L, Iyer SP, Sagert J, Pham MT, Tipton K, et al. CD70 expression in mature T-cell lymphomas. Blood [Internet]. 2021;138:4493\u20134493. Available from: https:\/\/doi.org\/10.1182\/blood-2021-146990.","journal-title":"Blood"},{"issue":"1","key":"985_CR280","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","volume":"26","author":"SP Iyer","year":"2025","unstructured":"Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, et al. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. The Lancet Oncol [Internet]. 2025;26(1):110\u201322. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(24)00508-4.","journal-title":"The Lancet Oncol"},{"key":"985_CR281","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1182\/blood-2023-184864","volume":"142","author":"H Rafei","year":"2023","unstructured":"Rafei H, Basar R, Acharya S, Zhang P, Liu P, Moseley SM, et al. Targeting T-cell lymphoma using CD70-directed cord blood-derived CAR-NK cells. Blood [Internet]. 2023;142:4811\u20134811. Available from: https:\/\/doi.org\/10.1182\/blood-2023-184864.","journal-title":"Blood"},{"issue":"3","key":"985_CR282","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/leu.2015.311","volume":"30","author":"K Pinz","year":"2016","unstructured":"Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia [Internet]. 2016;30(3):701\u201307. Available from: https:\/\/doi.org\/10.1038\/leu.2015.311.","journal-title":"Leukemia"},{"issue":"68","key":"985_CR283","doi-asserted-by":"publisher","first-page":"112783","DOI":"10.18632\/oncotarget.22626","volume":"8","author":"KG Pinz","year":"2017","unstructured":"Pinz KG, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH, et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget [Internet]. 2017;8(68):112783\u201396. Available from: https:\/\/doi.org\/10.18632\/oncotarget.22626.","journal-title":"Oncotarget"},{"key":"985_CR284","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1182\/blood-2022-162222","volume":"140","author":"H Qian","year":"2022","unstructured":"Qian H, Gay FPH, Pang JWL, Lee Y, Ang J, Tan HC, et al. Development of anti-CD3 chimeric antigen receptor (CAR)-T cells for allogeneic cell therapy of peripheral T-cell lymphoma (PTCL). Blood [Internet]. 2022;140:4510\u201311. Available from: https:\/\/doi.org\/10.1182\/blood-2022-162222.","journal-title":"Blood"},{"issue":"35","key":"985_CR285","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget [Internet]. 2016;7(35):56219\u201332. Available from: https:\/\/doi.org\/10.18632\/oncotarget.11019.","journal-title":"Oncotarget"},{"issue":"14","key":"985_CR286","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","volume":"7","author":"K Watanabe","year":"2023","unstructured":"Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, et al. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Adv [Internet]. 2023;7(14):3416\u201330. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2022008327.","journal-title":"Blood Adv"},{"issue":"14","key":"985_CR287","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarf\u00f2","year":"2018","unstructured":"Scarf\u00f2 I, Ormh\u00f8j M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood [Internet]. 2018;132(14):1495\u2013506. Available from: https:\/\/doi.org\/10.1182\/blood-2018-04-842708.","journal-title":"Blood"},{"issue":"11","key":"985_CR288","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1182\/blood.2024024104","volume":"144","author":"MJ Frigault","year":"2024","unstructured":"Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, et al. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood [Internet]. 2024;144(11):1153\u201367. Available from: https:\/\/doi.org\/10.1182\/blood.2024024104.","journal-title":"Blood"},{"key":"985_CR289","doi-asserted-by":"publisher","unstructured":"Zeng E, Zhan T, Wu Y, Chen M, Wang J, Zhang Y, et al. Preclinical analysis of an autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy for relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). J Clin Oncol [Internet]. 2021;39:e14510\u201314510. Available from: https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.e14510.","DOI":"10.1200\/jco.2021.39.15_suppl.e14510"},{"key":"985_CR290","doi-asserted-by":"publisher","first-page":"101125","DOI":"10.1016\/j.omtm.2023.101125","volume":"31","author":"CA Wills","year":"2023","unstructured":"Wills CA, Drago D, Pietrusko RG. Clinical holds for cell and gene therapy trials: risks, impact, and lessons learned. Mol ther methods Clin Dev [Internet]. Mol Ther Methods Clin Devel. 2023;31:101125. Available from: https:\/\/doi.org\/10.1016\/j.omtm.2023.101125.","journal-title":"Mol Ther Methods Clin Devel"},{"key":"985_CR291","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood-2024-200932","volume":"144","author":"N Grover","year":"2024","unstructured":"Grover N, Moore D, Ivanova A, Beaven AW, Dittus C, Cheng CJA, et al. CD30.CAR-T cells co-expressing the CCR4 chemokine receptor in relapsed\/refractory hodgkin lymphoma. Blood [Internet]. 2024;144:919\u2013919. Available from: https:\/\/doi.org\/10.1182\/blood-2024-200932.","journal-title":"Blood"},{"issue":"1","key":"985_CR292","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov [Internet]. 2022;12(1):31\u201346. Available from: https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"issue":"8","key":"985_CR293","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol [Internet]. 2015;15(8):486\u201399. Available from: https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"key":"985_CR294","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol [Internet]. 2018;8:386. Available from: https:\/\/doi.org\/10.3389\/fonc.2018.00386.","journal-title":"Front Oncol"},{"issue":"1","key":"985_CR295","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (gxplore-002). J Hematol Oncol [Internet]. 2021;14(1):12. Available from: https:\/\/doi.org\/10.1186\/s13045-021-01033-1.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"985_CR296","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","volume":"19","author":"SK Barta","year":"2019","unstructured":"Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk [Internet]. 2019;19(6):356\u201364.e3. Available from: https:\/\/doi.org\/10.1016\/j.clml.2019.03.022.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"985_CR297","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1182\/blood-2022-168983","volume":"140","author":"OO Agbedia","year":"2022","unstructured":"Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, et al. Updated results of an investigator-initiated phase II study of pembrolizumab and romidepsin for patients with relapsed or refractory T-cell lymphoma (TCL) with survival analysis. Blood [Internet]. 2022;140:2313\u201315. Available from: https:\/\/doi.org\/10.1182\/blood-2022-168983.","journal-title":"Blood"},{"key":"985_CR298","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-136061","volume":"136","author":"MJ Ahearne","year":"2020","unstructured":"Ahearne MJ, Gaskell C, Jackson AE, Morland C, Hopkins L, Nawaz N, et al. AVAIL-T: a phase 2a trial of avelumab, and anti-PD-L1 antibody, in relapsed and refractory peripheral T-Cell lymphoma (PTCL). Blood [Internet]. 2020;136:18\u201319. Available from: https:\/\/doi.org\/10.1182\/blood-2020-136061.","journal-title":"Blood"},{"issue":"9","key":"985_CR299","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/bloodadvances.2024014655","volume":"9","author":"C Querfeld","year":"2025","unstructured":"Querfeld C, Palmer J, Han Z, Wu X, Yuan Y-C, Chen M-H, et al. Phase 1 trial of durvalumab (anti\u2013PD-L1) combined with lenalidomide in relapsed\/refractory cutaneous T-cell lymphoma. Blood Adv [Internet]. 2025;9(9):2247\u201360. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2024014655.","journal-title":"Blood Adv"},{"issue":"1","key":"985_CR300","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol Rev [Internet]. 2017;276(1):145\u201364. Available from: https:\/\/doi.org\/10.1111\/imr.12527.","journal-title":"Immunol Rev"},{"issue":"2","key":"985_CR301","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell [Internet]. 2009;138(2):271\u201385. Available from: https:\/\/doi.org\/10.1016\/j.cell.2009.05.046.","journal-title":"Cell"},{"issue":"18","key":"985_CR302","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","volume":"118","author":"MP Chao","year":"2011","unstructured":"Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood [Internet]. 2011;118(18):4890\u2013901. Available from: https:\/\/doi.org\/10.1182\/blood-2011-02-338020.","journal-title":"Blood"},{"issue":"4","key":"985_CR303","first-page":"1351","volume":"41","author":"S Knauf","year":"1981","unstructured":"Knauf S, Urbach GI. Identification, purification, and radioimmunoassay of NB\/70K, a human ovarian tumor-associated antigen. Cancer Res [Internet]. 1981;41(4):1351\u201357. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6163521.","journal-title":"Cancer Res"},{"issue":"10","key":"985_CR304","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-18-3125","volume":"79","author":"D Ma","year":"2019","unstructured":"Ma D, Liu S, Lal B, Wei S, Wang S, Zhan D, et al. Extracellular matrix protein tenascin C increases phagocytosis mediated by CD47 loss of function in glioblastoma. Cancer Res [Internet]. 2019;79(10):2697\u2013708. Available from: https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3125.","journal-title":"Cancer Res"},{"key":"985_CR305","doi-asserted-by":"publisher","unstructured":"Safety concerns prompt pause of magrolimab trials. Cancer DiscovCancer Discov [Internet]. 2022;12(4):877\u201378. Available from: https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2022-0012.","DOI":"10.1158\/2159-8290.CD-NB2022-0012"},{"issue":"5","key":"985_CR306","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood [Internet]. 2025;146(5):601\u201311. Available from: https:\/\/doi.org\/10.1182\/blood.2024027506.","journal-title":"Blood"},{"key":"985_CR307","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2024-203706","volume":"144","author":"S Arora","year":"2024","unstructured":"Arora S, Senapati J, Loghavi S, Reville PK, Wang B, Kadia TM, et al. Phase 1b\/2 study of magrolimab (Magro), azacitidine (AZA) and venetoclax (VEN) in patients (pts) with newly diagnosed (ND) older\/unfit or high risk acute myeloid leukemia (AML) and relapsed refractory (R\/R) AML: final clinical data and genomic markers of resistance\/relapse. Blood [Internet]. 2024;144:735\u2013735. Available from: https:\/\/doi.org\/10.1182\/blood-2024-203706.","journal-title":"Blood"},{"key":"985_CR308","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2024-194771","volume":"144","author":"L Gui","year":"2024","unstructured":"Gui L, Zhou K, Liu T, Qin Y, Jing H, Li W, et al. A phase ib clinical trial investigating the safety, tolerability, and pharmacokinetics of HX009 a novel BsAb dual targeting PD-1 x CD47, in patients with EBV+ non-hodgkin lymphoma (NHL). Blood [Internet]. 2024;144:1741\u20131741. Available from: https:\/\/doi.org\/10.1182\/blood-2024-194771.","journal-title":"Blood"},{"key":"985_CR309","doi-asserted-by":"publisher","unstructured":"Patel K, Orlowski RZ, Doucette K, Maris M, Pianko MJ, Ramchandren R, et al. TTI-622-01: a phase 1a\/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma. J Clin Oncol [Internet]. 2022;40(16_suppl):TPS8071\u20138071. Available from: https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.tps8071.","DOI":"10.1200\/jco.2022.40.16_suppl.tps8071"},{"issue":"3","key":"985_CR310","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","volume":"35","author":"P Armand","year":"2021","unstructured":"Armand P, Lesokhin A, Borrello I, Timmerman J, Gutierrez M, Zhu L, et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies. Leukemia [Internet]. 2021;35(3):777\u201386. Available from: https:\/\/doi.org\/10.1038\/s41375-020-0939-1.","journal-title":"Leukemia"},{"issue":"22","key":"985_CR311","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","volume":"128","author":"S Ansell","year":"2016","unstructured":"Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood [Internet]. 2016;128(22):183\u2013183. Available from: https:\/\/doi.org\/10.1182\/blood.V128.22.183.183.","journal-title":"Blood"},{"issue":"25","key":"985_CR312","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med [Internet]. 2016;374(25):2419\u201329. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1510093.","journal-title":"N Engl J Med"},{"issue":"3","key":"985_CR313","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.annonc.2025.11.006","volume":"37","author":"J-M Michot","year":"2026","unstructured":"Michot J-M, Bologna S, Bastie J-N, Borght TV, Bri\u00e8re J, Ribrag V, et al. Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial. Ann Oncol [Internet]. 2026;37(3):403\u201313. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2025.11.006.","journal-title":"Ann Oncol"},{"issue":"21","key":"985_CR314","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, D\u00f6hner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood [Internet]. 2014;123(21):3247\u201354. Available from: https:\/\/doi.org\/10.1182\/blood-2014-01-546150.","journal-title":"Blood"},{"issue":"3","key":"985_CR315","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3324\/haematol.2014.109777","volume":"100","author":"L-A Sutton","year":"2015","unstructured":"Sutton L-A, Ljungstr\u00f6m V, Mansouri L, Young E, Cortese D, Navrkalova V, et al. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica [Internet]. 2015;100(3):370\u201376. Available from: https:\/\/doi.org\/10.3324\/haematol.2014.109777.","journal-title":"Haematologica"},{"issue":"17","key":"985_CR316","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2025015791","volume":"9","author":"L Meriranta","year":"2025","unstructured":"Meriranta L, Rask Kragh J\u00f8rgensen R, Pasanen A, Kolstad A, Hutchings M, Niemann CU, et al. Circulating tumor DNA determinants of response and outcome in relapsed\/refractory mantle cell lymphoma. Blood Adv [Internet]. 2025;9(17):4528\u201341. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2025015791.","journal-title":"Blood Adv"},{"issue":"1","key":"985_CR317","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/hematology.2021000247","volume":"2021","author":"K Dunleavy","year":"2021","unstructured":"Dunleavy K. Double-hit lymphoma: optimizing therapy. Hematol Am Soc Hematol Educ Program [Internet]. 2021;2021(1):157\u201363. Available from: https:\/\/doi.org\/10.1182\/hematology.2021000247.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"985_CR318","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ajh.26068","volume":"96","author":"M-C Laude","year":"2021","unstructured":"Laude M-C, Lebras L, Sesques P, Ghesquieres H, Favre S, Bouabdallah K, et al. First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study. Am J Hematol [Internet]. 2021;96(3):302\u201311. Available from: https:\/\/doi.org\/10.1002\/ajh.26068.","journal-title":"Am J Hematol"},{"issue":"35","key":"985_CR319","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1200\/JCO.19.00743","volume":"37","author":"A Rosenwald","year":"2019","unstructured":"Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn M-H, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma Biomarker consortium. J Clin Oncol [Internet]. 2019;37(35):3359\u201368. Available from: https:\/\/doi.org\/10.1200\/JCO.19.00743.","journal-title":"J Clin Oncol"},{"issue":"4","key":"985_CR320","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med [Internet]. 2022;386(4):351\u201363. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"issue":"2","key":"985_CR321","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/1758834009360519","volume":"2","author":"S Mehta","year":"2010","unstructured":"Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol [Internet]. 2010;2(2):125\u201348. Available from: https:\/\/doi.org\/10.1177\/1758834009360519.","journal-title":"Ther Adv Med Oncol"},{"key":"985_CR322","doi-asserted-by":"crossref","unstructured":"A predictive Model for aggressive Non-Hodgkin\u2019s lymphoma. N Engl J Med [Internet]. 1993;329(14):987\u201394. Available from: 10.1056\/NEJM199309303291402.","DOI":"10.1056\/NEJM199309303291402"},{"key":"985_CR323","doi-asserted-by":"publisher","unstructured":"Sibon D, Nguyen D-P, Schmitz N, Suzuki R, Feldman AL, Gressin R, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica [Internet]. 2019;104(12):e562\u20135. Available from: https:\/\/doi.org\/10.3324\/haematol.2018.213512.","DOI":"10.3324\/haematol.2018.213512"},{"issue":"2","key":"985_CR324","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","volume":"83","author":"AJM Ferreri","year":"2012","unstructured":"Ferreri AJM, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol [Internet]. 2012;83(2):293\u2013302. Available from: https:\/\/doi.org\/10.1016\/j.critrevonc.2012.02.005.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"985_CR325","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2022.281222","volume":"108","author":"L Qiu","year":"2023","unstructured":"Qiu L, Tang G, Li S, Vega F, Lin P, Wang SA, et al. DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica [Internet]. 2023;108(6):1604\u201315. Available from: https:\/\/doi.org\/10.3324\/haematol.2022.281222.","journal-title":"Haematologica"},{"key":"985_CR326","doi-asserted-by":"publisher","unstructured":"Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol [Internet]. 2019;186(3):e28\u201331. Available from: https:\/\/doi.org\/10.1111\/bjh.15860.","DOI":"10.1111\/bjh.15860"},{"key":"985_CR327","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/BLOOD.V130.SUPPL_1.822.822","volume":"130","author":"MB Pedersen","year":"2017","unstructured":"Pedersen MB, Relander T, Lauritzsen GF, Ellin F, Lepp\u00e4 S, Mannisto S, et al. The impact of upfront autologous transplant on the survival of adult patients with ALCL and PTCL-NOS according to their ALK, DUSP22 and TP63 gene rearrangement status - a joined Nordic lymphoma group and Mayo Clinic analysis. Blood [Internet]. 2017;130:822\u2013822. Available from: https:\/\/doi.org\/10.1182\/BLOOD.V130.SUPPL_1.822.822.","journal-title":"Blood"},{"issue":"1","key":"985_CR328","doi-asserted-by":"publisher","first-page":"9746716","DOI":"10.1155\/2020\/9746716","volume":"2020","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang X, Qin H, Zhao Z, Li J, Zhang B, et al. Prognostic values of baseline 18F-FDG PET\/CT in patients with peripheral T-cell lymphoma. Biomed Res Int [Internet]. 2020, 2020: 2020(1):9746716. Available from: https:\/\/doi.org\/10.1155\/2020\/9746716.","journal-title":"Biomed Res Int"},{"issue":"11","key":"985_CR329","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2025031480","volume":"147","author":"J Cloos","year":"2026","unstructured":"Cloos J, Valk PJM, Thiede C, D\u00f6hner K, Roboz GJ, Wood BL, et al. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD working party. Blood [Internet]. 2025, Available from: 2026;147(11):1147\u201367. https:\/\/doi.org\/10.1182\/blood.2025031480.","journal-title":"Blood"},{"issue":"7","key":"985_CR330","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","volume":"38","author":"S Scott","year":"2024","unstructured":"Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE, et al. Recommendations from the AML molecular MRD expert advisory board. Leukemia [Internet]. 2024;38(7):1638\u201341. Available from: https:\/\/doi.org\/10.1038\/s41375-024-02275-x.","journal-title":"Leukemia"},{"issue":"8","key":"985_CR331","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","volume":"6","author":"R Lakhotia","year":"2022","unstructured":"Lakhotia R, Melani C, Dunleavy K, Pittaluga S, Saba N, Lindenberg L, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv [Internet]. 2022;6(8):2667\u201380. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2021006397.","journal-title":"Blood Adv"},{"issue":"1","key":"985_CR332","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12964-025-02438-y","volume":"23","author":"J-H Liang","year":"2025","unstructured":"Liang J-H, Hua W, Yin H, Li Y, Zhang X-Y, Liang J-H, et al. Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study. Cell Commun Signal [Internet]. 2025;23(1):441. Available from: https:\/\/doi.org\/10.1186\/s12964-025-02438-y.","journal-title":"Cell Commun Signal"},{"key":"985_CR333","doi-asserted-by":"publisher","unstructured":"Donglu Z, Yuqin S, Jiayue Q, Hongyan T, Kaiyang D, Qingqing C, et al. Mutation profiling, efficacy monitoring, and prognosis evaluation using circulating tumor DNA in peripheral T-cell lymphoma: a prospective, multicenter, observational study. Am J Hematol [Internet]. 2026, Available from: https:\/\/doi.org\/10.1002\/ajh.70357.","DOI":"10.1002\/ajh.70357"},{"key":"985_CR334","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1182\/blood-2024-207594","volume":"144","author":"N Mehta-Shah","year":"2024","unstructured":"Mehta-Shah N, Horwitz S, Zinzani PL, Barta SK, Yamagishi M, Kurtz DM, et al. Prediction of clinical response by PhasED variants in circulating tumor DNA (ctDNA) in the VALENTINE-PTCL01 trial of patients with relapsed or refractory (R\/R) peripheral T-cell lymphoma (PTCL). Blood [Internet]. 2024;144:4342\u20134342. Available from: https:\/\/doi.org\/10.1182\/blood-2024-207594.","journal-title":"Blood"},{"issue":"1","key":"985_CR335","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/bjc.2014.211","volume":"111","author":"C Le Tourneau","year":"2014","unstructured":"Le Tourneau C, Paoletti X, Servant N, Bi\u00e8che I, Gentien D, Rio Frio T, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer [Internet]. 2014;111(1):17\u201324. Available from: https:\/\/doi.org\/10.1038\/bjc.2014.211.","journal-title":"Br J Cancer"},{"issue":"21","key":"985_CR336","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V122.21.483.483","volume":"122","author":"KY Yeung","year":"2013","unstructured":"Yeung KY, Blau CA, Oehler VG, Lee S-I, Miller CP, Chien S, et al. Personalized approach to treatment of acute myeloid leukemia using a high-throughput chemosensitivity assay. Blood [Internet]. 2013;122(21):483\u2013483. Available from: https:\/\/doi.org\/10.1182\/blood.V122.21.483.483.","journal-title":"Blood"},{"issue":"22","key":"985_CR337","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.V128.22.1675.1675","volume":"128","author":"L Rocchi","year":"2016","unstructured":"Rocchi L, Faenza A, Rambelli L, Guadagnuolo V, Marconi G, Simonetti G, et al. Ex-vivo drug response profiling for precision medicine approaches in acute myeloid leukemia with the open microwell microfluidic platform. Blood [Internet]. 2016;128(22):1675\u20131675. Available from: https:\/\/doi.org\/10.1182\/blood.V128.22.1675.1675.","journal-title":"Blood"},{"key":"985_CR338","doi-asserted-by":"publisher","unstructured":"Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood [Internet]. 2017;129(11):e26\u201337. Available from: https:\/\/doi.org\/10.1182\/blood-2016-09-738070.","DOI":"10.1182\/blood-2016-09-738070"},{"key":"985_CR339","doi-asserted-by":"publisher","unstructured":"Snijder B, Vladimer GI, Krall N, Miura K, Schmolke A-S, Kornauth C, et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol [Internet]. 2017;4(12):e595\u2013606. Available from: https:\/\/doi.org\/10.1016\/S2352-3026(17)30208-9.","DOI":"10.1016\/S2352-3026(17)30208-9"},{"issue":"12","key":"985_CR340","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov [Internet]. 2013;3(12):1416\u201329. Available from: https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0350.","journal-title":"Cancer Discov"},{"key":"985_CR341","doi-asserted-by":"publisher","unstructured":"Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci Transl Med [Internet]. 2018;10(453):eaan0941. Available from: https:\/\/doi.org\/10.1126\/scitranslmed.aan0941.","DOI":"10.1126\/scitranslmed.aan0941"},{"key":"985_CR342","doi-asserted-by":"publisher","unstructured":"Lee RX, Mohd Abdul Rashid MB, Binte Meera Sahib NR, Goh J, De Mel S, Batumalai Y. Prospective clinical validation of a combinatorial functional precision medicine platform in Relapsed\/Refractory non-Hodgkin\u2019s lymphoma. JCO Precis Oncol [Internet]. 2025;9(9):e2400780. Available from: https:\/\/doi.org\/10.1200\/PO-24-00780.","DOI":"10.1200\/PO-24-00780"},{"key":"985_CR343","doi-asserted-by":"publisher","unstructured":"Goh J, De Mel S, Hoppe MM, Mohd Abdul Rashid MB, Zhang XY, Jaynes P, et al. An ex vivo platform to guide drug combination treatment in relapsed\/refractory lymphoma. Sci Transl Med [Internet]. 2022;14(667):eabn7824. Available from: https:\/\/doi.org\/10.1126\/scitranslmed.abn7824.","DOI":"10.1126\/scitranslmed.abn7824"},{"issue":"4","key":"985_CR344","doi-asserted-by":"publisher","first-page":"1900122","DOI":"10.1002\/adtp.201900122","volume":"3","author":"JJ Lim","year":"2020","unstructured":"Lim JJ, Goh J, Rashid MBMA, Chow EK-H. Maximizing efficiency of artificial intelligence-driven drug combination optimization through minimal resolution experimental design. Adv Ther (Weinh) [Internet]. 2020;3(4):1900122. Available from: https:\/\/doi.org\/10.1002\/adtp.201900122.","journal-title":"Adv Ther (Weinh)"},{"issue":"37","key":"985_CR345","doi-asserted-by":"publisher","first-page":"10442","DOI":"10.1073\/pnas.1606301113","volume":"113","author":"A Zimmer","year":"2016","unstructured":"Zimmer A, Katzir I, Dekel E, Mayo AE, Alon U. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Natl Acad Sci U S A [Internet]. 2016;113(37):10442\u201347. Available from: https:\/\/doi.org\/10.1073\/pnas.1606301113.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6481","key":"985_CR346","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaz3023","volume":"367","author":"D Ho","year":"2020","unstructured":"Ho D. Artificial intelligence in cancer therapy. Science [Internet]. 2020;367(6481):982\u201383. Available from: https:\/\/doi.org\/10.1126\/science.aaz3023.","journal-title":"Science"},{"issue":"119","key":"985_CR347","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1098\/rsif.2016.0332","volume":"13","author":"E Tekin","year":"2016","unstructured":"Tekin E, Beppler C, White C, Mao Z, Savage VM, Yeh PJ. Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. J R Soc Interface [Internet]. 2016;13(119):13. Available from: https:\/\/doi.org\/10.1098\/rsif.2016.0332.","journal-title":"J R Soc Interface"},{"issue":"1","key":"985_CR348","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41408-020-0276-7","volume":"10","author":"S de Mel","year":"2020","unstructured":"de Mel S, Rashid MBM, Zhang XY, Goh J, Lee CT, Poon LM, et al. Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. Blood Cancer J [Internet]. 2020;10(1):9. Available from: https:\/\/doi.org\/10.1038\/s41408-020-0276-7.","journal-title":"Blood Cancer J"},{"issue":"3","key":"985_CR349","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-Cell lymphomas, version 2. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw [Internet]. 2022;20(3):285\u2013308. Available from: https:\/\/doi.org\/10.6004\/jnccn.2022.0015.","journal-title":"J Natl Compr Canc Netw"},{"key":"985_CR350","doi-asserted-by":"publisher","unstructured":"Superchi C, Brion Bouvier F, Gerardi C, Carmona M, San Miguel L, S\u00e1nchez-G\u00f3mez LM, et al. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open [Internet]. 2022;12(5):e052926. Available from: https:\/\/doi.org\/10.1136\/bmjopen-2021-052926.","DOI":"10.1136\/bmjopen-2021-052926"},{"issue":"1","key":"985_CR351","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"X-P Duan","year":"2024","unstructured":"Duan X-P, Qin B-D, Jiao X-D, Liu K, Wang Z, Zang Y-S. New clinical trial design in precision medicine: discovery, development and direction. Sig Transduct Target Ther [Internet]. 2024;9(1):57. Available from: https:\/\/doi.org\/10.1038\/s41392-024-01760-0.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"985_CR352","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med [Internet]. 2022;14(1):101. Available from: https:\/\/doi.org\/10.1186\/s13073-022-01102-1.","journal-title":"Genome Med"},{"issue":"12","key":"985_CR353","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International peripheral T-Cell lymphoma project. Blood [Internet]. 2008;111(12):5496\u2013504. Available from: https:\/\/doi.org\/10.1182\/blood-2008-01-134270.","journal-title":"Blood"},{"issue":"1","key":"985_CR354","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","volume":"126","author":"G Hapgood","year":"2015","unstructured":"Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood [Internet]. 2015;126(1):17\u201325. Available from: https:\/\/doi.org\/10.1182\/blood-2014-10-567461.","journal-title":"Blood"},{"issue":"1","key":"985_CR355","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther [Internet]. 2024;9(1):336. Available from: https:\/\/doi.org\/10.1038\/s41392-024-02021-w.","journal-title":"Sig Transduct Target Ther"},{"key":"985_CR356","doi-asserted-by":"publisher","unstructured":"Pandey S, Yadav P. Liquid biopsy in cancer management: Integrating diagnostics and clinical applications. Pract Lab Med [Internet]. 2025;43:e00446. Available from: https:\/\/doi.org\/10.1016\/j.plabm.2024.e00446.","DOI":"10.1016\/j.plabm.2024.e00446"},{"issue":"2","key":"985_CR357","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.16971","volume":"191","author":"G Smith","year":"2020","unstructured":"Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al. A British society for haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol [Internet]. 2020;191(2):171\u201393. Available from: https:\/\/doi.org\/10.1111\/bjh.16971.","journal-title":"Br J Haematol"},{"issue":"4","key":"985_CR358","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia [Internet]. 2020;34(4):966\u201384. Available from: https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"issue":"10","key":"985_CR359","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw [Internet]. 2020;18(10):1385\u2013415. Available from: https:\/\/doi.org\/10.6004\/jnccn.2020.0047.","journal-title":"J Natl Compr Canc Netw"},{"key":"985_CR360","doi-asserted-by":"publisher","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon F-X, Janssen JJWM, Hjorth-Hansen H, et al. Corrections to \u201cchronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u201d. Ann Oncol [Internet]. 2018;29:iv261. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdy159.","DOI":"10.1093\/annonc\/mdy159"},{"issue":"4","key":"985_CR361","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11899-024-00736-9","volume":"19","author":"V Tran","year":"2024","unstructured":"Tran V, Salafian K, Michaels K, Jones C, Reed D, Keng M, et al. MRD in Philadelphia chromosome-positive ALL: methodologies and clinical implications. Curr Hematol Malig Rep [Internet]. 2024;19(4):186\u201396. Available from: https:\/\/doi.org\/10.1007\/s11899-024-00736-9.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00985-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:00:44Z","timestamp":1787695244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00985-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":361,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00985-1","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}